[10-Q] The Vita Coco Company, Inc. Quarterly Earnings Report

Q: How much did The Vita Coco Company (COCO) earn per share in Q2 2025?

Diluted EPS was $0.38 , up from $0.32 in Q2 2024.

Q: What was Vita Coco’s revenue growth in the second quarter of 2025?

Net sales rose 17% year over year to $168.8 million .

Q: How much cash does COCO have and is it carrying debt?

As of 6/30/25, the company held $167 million in cash and had no outstanding borrowings on its $60 million revolver.

Q: What is the status of the share repurchase program?

COCO repurchased 284,728 shares for $8.6 m in Q2; $42.1 m remains authorized.

Q: How reliant is Vita Coco on major customers?

Two customers account for 45% of year-to-date net sales , indicating high customer concentration risk.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

10-Q

Rhea-AI Filing Summary

Q2 FY25 highlights (ended 6/30/25):

Net sales rose 17% YoY to $168.8 m; Americas +14%, International +37%.
Gross profit increased 4% to $61.3 m, but margin compressed to 36.3% (-440 bp) as coconut input and logistics costs outpaced pricing.
SG&A up 26% to $36.1 m (marketing and stock-based comp), driving a 16% drop in operating income to $25.1 m.
Derivative gains ($1.1 m vs -$6.0 m) and FX gains lifted net income 20% to $22.9 m; diluted EPS $0.38 vs $0.32.
Six-month net sales +17% to $299.7 m; net income +26% to $41.8 m; diluted EPS $0.70.
Balance sheet robust: cash & equivalents $167 m, no revolver borrowings, net cash position. Equity climbed to $297 m. Purchase of 284,728 shares in Q2 ($8.6 m); $42.1 m authorization remains.
Two customers represent 45% of YTD sales; private-label volumes expected to decline in H2.
Tariff environment volatile: 10% baseline U.S. import tariff already impacting COGS; proposed 50% tariff on Brazilian sourcing could pressure margins further.

Liquidity: positive operating cash flow of $12 m YTD; undrawn $60 m credit facility extended to 2030.

Key watch-points for investors: ability to pass through cost inflation, tariff developments, customer concentration risk, and progress of international expansion.

Insights

TL;DR: Solid top-line growth and clean balance sheet offset by margin pressure and tariff risk.

Revenue beat (+17% YoY) shows resilient demand for Vita Coco’s core coconut water and strong momentum internationally. However, gross margin fell sharply as freight and input costs rose faster than pricing. SG&A growth outpaced sales, leading to lower operating income. EPS growth came mainly from derivative and FX swings—quality of earnings therefore mixed. Cash generation, lack of net debt, and buyback runway offer downside protection. Valuation hinges on management’s ability to defend margins amid new U.S. import tariffs (10% in place, 50% proposed on Brazil) and navigate looming private-label volume losses at a 45% customer concentration level.

TL;DR: Margin compression, tariff exposure, and customer concentration elevate risk profile.

Despite ample liquidity, COCO faces several heightened risks: 1) Tariff regime could raise COGS materially—Brazil supplies a large share of coconut water. 2) Two customers account for 45% of sales and one is scaling back private-label orders; revenue diversification is critical. 3) Gross margin contraction of 440 bp suggests limited pricing power relative to cost inflation. 4) Share repurchases help EPS but reduce cash flexibility if tariffs linger. Overall impact assessed as neutral currently; watch for H2 margin guidance and customer retention metrics.

07/30/2025 - 09:01 AM

0001482981December 312025Q2false232391367367184xbrli:sharesiso4217:USDiso4217:USDxbrli:sharescoco:subsidiaryxbrli:purecoco:votecoco:segmentcoco:offering00014829812025-01-012025-06-3000014829812025-07-2800014829812025-06-3000014829812024-12-3100014829812025-04-012025-06-3000014829812024-04-012024-06-3000014829812024-01-012024-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2023-12-310001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2023-12-310001482981us-gaap:CommonStockMember2023-12-310001482981us-gaap:AdditionalPaidInCapitalMember2023-12-310001482981us-gaap:RetainedEarningsMember2023-12-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001482981us-gaap:TreasuryStockCommonMember2023-12-310001482981us-gaap:ParentMember2023-12-310001482981us-gaap:RetainedEarningsMember2024-01-012024-03-310001482981us-gaap:ParentMember2024-01-012024-03-310001482981us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001482981us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001482981coco:CommonClassMemberus-gaap:CommonStockMember2024-01-012024-03-310001482981us-gaap:CommonStockMember2024-01-012024-03-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001482981coco:CommonClassMemberus-gaap:CommonStockMember2024-03-310001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2024-03-310001482981us-gaap:CommonStockMember2024-03-310001482981us-gaap:AdditionalPaidInCapitalMember2024-03-310001482981us-gaap:RetainedEarningsMember2024-03-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001482981us-gaap:TreasuryStockCommonMember2024-03-310001482981us-gaap:ParentMember2024-03-310001482981us-gaap:RetainedEarningsMember2024-04-012024-06-300001482981us-gaap:ParentMember2024-04-012024-06-300001482981us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2024-04-012024-06-300001482981us-gaap:CommonStockMember2024-04-012024-06-300001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2024-06-300001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2024-06-300001482981us-gaap:CommonStockMember2024-06-300001482981us-gaap:AdditionalPaidInCapitalMember2024-06-300001482981us-gaap:RetainedEarningsMember2024-06-300001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001482981us-gaap:TreasuryStockCommonMember2024-06-300001482981us-gaap:ParentMember2024-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2024-12-310001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2024-12-310001482981us-gaap:CommonStockMember2024-12-310001482981us-gaap:AdditionalPaidInCapitalMember2024-12-310001482981us-gaap:RetainedEarningsMember2024-12-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001482981us-gaap:TreasuryStockCommonMember2024-12-310001482981us-gaap:ParentMember2024-12-310001482981us-gaap:RetainedEarningsMember2025-01-012025-03-310001482981us-gaap:ParentMember2025-01-012025-03-310001482981us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001482981us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001482981coco:CommonClassMemberus-gaap:CommonStockMember2025-01-012025-03-310001482981us-gaap:CommonStockMember2025-01-012025-03-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001482981coco:CommonClassMemberus-gaap:CommonStockMember2025-03-310001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2025-03-310001482981us-gaap:CommonStockMember2025-03-310001482981us-gaap:AdditionalPaidInCapitalMember2025-03-310001482981us-gaap:RetainedEarningsMember2025-03-310001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001482981us-gaap:TreasuryStockCommonMember2025-03-310001482981us-gaap:ParentMember2025-03-310001482981us-gaap:RetainedEarningsMember2025-04-012025-06-300001482981us-gaap:ParentMember2025-04-012025-06-300001482981us-gaap:TreasuryStockCommonMember2025-04-012025-06-300001482981us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2025-04-012025-06-300001482981us-gaap:CommonStockMember2025-04-012025-06-300001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001482981coco:CommonClassMemberus-gaap:CommonStockMember2025-06-300001482981coco:CommonClassWithExitWarrantsMemberus-gaap:CommonStockMember2025-06-300001482981us-gaap:CommonStockMember2025-06-300001482981us-gaap:AdditionalPaidInCapitalMember2025-06-300001482981us-gaap:RetainedEarningsMember2025-06-300001482981us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001482981us-gaap:TreasuryStockCommonMember2025-06-300001482981us-gaap:ParentMember2025-06-3000014829812023-12-3100014829812024-06-300001482981srt:SubsidiariesMember2025-01-012025-06-300001482981srt:AsiaMembersrt:SubsidiariesMember2025-01-012025-06-300001482981srt:NorthAmericaMembersrt:SubsidiariesMember2025-01-012025-06-300001482981country:DEsrt:SubsidiariesMember2025-01-012025-06-300001482981coco:CocoVenturesMember2025-06-300001482981coco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001482981coco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-06-300001482981coco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-06-300001482981coco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:AmericasSegmentMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:InternationalSegmentMember2025-04-012025-06-300001482981coco:VitaCocoCoconutWaterMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:AmericasSegmentMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:InternationalSegmentMember2025-04-012025-06-300001482981coco:PrivateLabelMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:AmericasSegmentMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:InternationalSegmentMember2025-04-012025-06-300001482981us-gaap:ProductAndServiceOtherMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2025-04-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:AmericasSegmentMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:InternationalSegmentMember2024-04-012024-06-300001482981coco:VitaCocoCoconutWaterMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:AmericasSegmentMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:InternationalSegmentMember2024-04-012024-06-300001482981coco:PrivateLabelMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:AmericasSegmentMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:InternationalSegmentMember2024-04-012024-06-300001482981us-gaap:ProductAndServiceOtherMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2024-04-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:AmericasSegmentMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:InternationalSegmentMember2025-01-012025-06-300001482981coco:VitaCocoCoconutWaterMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:AmericasSegmentMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:InternationalSegmentMember2025-01-012025-06-300001482981coco:PrivateLabelMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:AmericasSegmentMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:InternationalSegmentMember2025-01-012025-06-300001482981us-gaap:ProductAndServiceOtherMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:AmericasSegmentMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:VitaCocoCoconutWaterMembercoco:InternationalSegmentMember2024-01-012024-06-300001482981coco:VitaCocoCoconutWaterMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:AmericasSegmentMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:PrivateLabelMembercoco:InternationalSegmentMember2024-01-012024-06-300001482981coco:PrivateLabelMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:AmericasSegmentMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercoco:InternationalSegmentMember2024-01-012024-06-300001482981us-gaap:ProductAndServiceOtherMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2024-01-012024-06-300001482981coco:VehicleLoansMember2025-06-300001482981coco:VehicleLoansMember2024-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2020-05-012020-05-310001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2020-05-310001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2025-02-150001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2025-02-140001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2025-06-300001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2024-01-012024-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2024-01-012024-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2025-02-142025-02-140001482981coco:TwoThousandAndTwentyCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2025-02-142025-02-140001482981coco:TwoThousandAndTwentyCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310001482981coco:TwoThousandAndTwentyCreditFacilityMember2024-01-012024-06-300001482981coco:TwoThousandAndTwentyCreditFacilityMember2025-01-012025-06-300001482981coco:TwoThousandAndTwentyCreditFacilityMember2025-04-012025-06-300001482981coco:TwoThousandAndTwentyCreditFacilityMember2024-04-012024-06-300001482981coco:VehicleLoansMembersrt:MinimumMemberus-gaap:NotesPayableOtherPayablesMember2025-06-300001482981coco:VehicleLoansMembersrt:MaximumMemberus-gaap:NotesPayableOtherPayablesMember2025-06-300001482981coco:VehicleLoansMemberus-gaap:NotesPayableOtherPayablesMember2025-06-300001482981coco:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001482981coco:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-06-300001482981coco:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-06-300001482981coco:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001482981coco:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001482981coco:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-06-300001482981coco:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-06-300001482981coco:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001482981us-gaap:RestrictedStockMember2021-10-012021-10-310001482981coco:OneCustomerMember2023-03-312023-03-310001482981coco:OneCustomerMember2024-03-312024-03-310001482981coco:SupplierAMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2025-01-012025-06-300001482981coco:SupplierAMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-06-300001482981coco:SupplierBMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2025-01-012025-06-300001482981coco:SupplierBMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-06-300001482981coco:SupplierCMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2025-01-012025-06-300001482981coco:SupplierCMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-06-300001482981coco:ReceiveBRLSellUSDMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveTHBSellUSDMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveEURPayUSDMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveUSDPayGBPMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveUSDPayEURMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveUSDSellTHBMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveUSDPayCADMemberus-gaap:NondesignatedMember2025-06-300001482981coco:ReceiveUSDPayEURMemberus-gaap:NondesignatedMember2024-12-310001482981coco:ReceiveUSDPayGBPMemberus-gaap:NondesignatedMember2024-12-310001482981coco:ReceiveUSDPayCADMemberus-gaap:NondesignatedMember2024-12-310001482981coco:ReceiveTHBSellUSDMemberus-gaap:NondesignatedMember2024-12-310001482981coco:ReceiveBRLSellUSDMemberus-gaap:NondesignatedMember2024-12-310001482981us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001482981us-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001482981us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001482981us-gaap:FairValueMeasurementsRecurringMember2025-06-300001482981us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001482981us-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001482981us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001482981us-gaap:FairValueMeasurementsRecurringMember2024-12-310001482981coco:A2021IncentiveAwardPlanMember2025-06-300001482981coco:A2021IncentiveAwardPlanMember2024-12-3100014829812023-10-3000014829812025-04-280001482981us-gaap:CommonStockMember2025-01-012025-06-300001482981us-gaap:CommonStockMember2024-01-012024-12-3100014829812024-01-012024-12-310001482981coco:A2014StockOptionAndRestrictedStockPlanMember2025-01-012025-06-300001482981srt:MaximumMembercoco:A2021IncentiveAwardPlanMember2025-06-300001482981coco:A2021IncentiveAwardPlanMember2025-01-012025-06-300001482981us-gaap:SalesMember2025-04-012025-06-300001482981us-gaap:SalesMember2024-04-012024-06-300001482981us-gaap:SalesMember2025-01-012025-06-300001482981us-gaap:SalesMember2024-01-012024-06-300001482981us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-04-012025-06-300001482981us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001482981us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-06-300001482981us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001482981us-gaap:RestrictedStockMember2025-06-300001482981us-gaap:RestrictedStockMember2025-01-012025-06-300001482981coco:A2014StockOptionAndRestrictedStockPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-01-012025-06-300001482981coco:A2014StockOptionAndRestrictedStockPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-01-012025-06-300001482981coco:ServiceBasedStockOptionsMember2024-12-310001482981coco:ServiceBasedStockOptionsMember2025-01-012025-06-300001482981coco:ServiceBasedStockOptionsMember2025-06-300001482981coco:ServiceBasedStockOptionsMember2024-01-012024-06-300001482981coco:PerformanceAndMarketBasedStockOptionsMember2024-12-310001482981coco:PerformanceAndMarketBasedStockOptionsMember2025-01-012025-06-300001482981coco:PerformanceAndMarketBasedStockOptionsMember2025-06-300001482981us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001482981us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001482981us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001482981us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2025-06-300001482981us-gaap:OperatingSegmentsMembercoco:AmericasSegmentMember2024-12-310001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2025-06-300001482981us-gaap:OperatingSegmentsMembercoco:InternationalSegmentMember2024-12-310001482981us-gaap:OperatingSegmentsMembercountry:US2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercountry:US2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMembercountry:GB2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMembercountry:GB2024-01-012024-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2025-01-012025-06-300001482981us-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2024-01-012024-06-300001482981country:SG2025-06-300001482981country:SG2024-12-310001482981country:US2025-06-300001482981country:US2024-12-310001482981country:GB2025-06-300001482981country:GB2024-12-310001482981us-gaap:NonUsMember2025-06-300001482981us-gaap:NonUsMember2024-12-3100014829812024-01-012024-03-3100014829812023-05-012023-05-3100014829812023-11-012023-11-300001482981coco:CocoVenturesMember2024-08-020001482981coco:NewYorkOfficeLeaseTenYearLeaseMember2024-08-310001482981coco:NewYorkOfficeLeaseTenYearLeaseMember2025-06-300001482981coco:LeaseSecurityDepositMemberus-gaap:LineOfCreditMembercoco:NewYorkOfficeLeaseTenYearLeaseMember2025-06-300001482981coco:LondonOfficeLeaseFiveYearLeaseMember2025-06-300001482981coco:SingaporeOfficeLeaseMember2025-06-300001482981coco:CoreyBakerMember2025-04-012025-06-300001482981coco:CoreyBakerMember2025-06-300001482981coco:TheMichaelKirban2012TrustMember2025-04-012025-06-300001482981coco:TheMichaelKirban2012TrustMember2025-06-300001482981coco:IraLiranMember2025-04-012025-06-300001482981coco:IraLiranMember2025-06-300001482981coco:TheIraLiran2012FamilyTrustMember2025-04-012025-06-300001482981coco:TheIraLiran2012FamilyTrustMember2025-06-300001482981coco:CharlesVanEsMember2025-04-012025-06-300001482981coco:CharlesVanEsMember2025-06-30

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM 10-Q

____________________

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-40950

____________________

The Vita Coco Company, Inc.

(Exact Name of Registrant as Specified in its Charter)

____________________


Delaware						11-3713156
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

250 Park Avenue South Seventh Floor New York, NY						10003
(Address of principal executive offices)						(Zip Code)

(212) 206-0763

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

____________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, Par Value $0.01 Per Share

COCO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	o
Emerging growth company	o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of July 28, 2025, there were 56,822,981 shares of the registrant’s common stock, par value $0.01 per share, outstanding.

Table of Contents

TABLE OF CONTENTS


		Page

PART I - FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024	5
	Condensed Consolidated Statements of Operations & Other Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024	6
	Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024	7
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
Item 4.	Controls and Procedures	35

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	36
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3.	Defaults Upon Senior Securities	36
Item 4.	Mine Safety Disclosures	36
Item 5.	Other Information	36
Item 6.	Exhibits	38
Signatures		40

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding our future results of operations and financial position, industry and business trends, equity compensation, business strategy, projected costs, plans, prospects, expectations, market growth, new products, supply chain predictions, and our objectives for future operations.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information, future events or otherwise.

As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context requires otherwise, the terms “Vita Coco,” the “Company,” “we,” “us,” and “our” refer to The Vita Coco Company, Inc. and its consolidated subsidiaries.

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

THE VITA COCO COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(Amounts in thousands, except share data)


	June 30, 2025		December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	167,042	$	164,669
Accounts receivable, net of allowance of $2,783 at June 30, 2025, and $2,255 at December 31, 2024	102,551		63,450
Inventory	84,110		83,600
Supplier advances, current	1,154		954
Derivative assets	1,174		1,382

Prepaid expenses and other current assets	30,713		27,236
Total current assets	386,744		341,291
Property and equipment, net	3,461		2,351
Goodwill	7,791		7,791

Supplier advances, long-term	2,130		2,254
Deferred tax assets, net	6,098		6,100
Right-of-use assets, net	12,222		385
Other assets	2,631		2,209
Total assets	$	421,077	$	362,381
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	25,834	$	30,758
Accrued expenses and other current liabilities	81,399		65,603
Notes payable, current	8		10
Derivative liabilities	2,802		6,895
Total current liabilities	110,043		103,266

Notes payable, long-term	—		3

Operating lease liability, long-term	13,996		—
Other long-term liabilities	99		295
Total liabilities	124,138		103,564
Commitments and contingencies (See Note 7)
Stockholders’ equity:
Common stock, $0.01 par value; 500,000,000 shares authorized; 63,877,128 and 63,702,387 shares issued at June 30, 2025 and December 31, 2024, respectively 56,802,981 and 56,961,941 shares outstanding at June 30, 2025 and December 31, 2024, respectively	639		637
Additional paid-in capital	178,774		174,077

Retained earnings	198,484		156,694
Accumulated other comprehensive income (loss)	826		(860)
Treasury stock, 7,074,147 shares at cost as of June 30, 2025, and 6,740,446 shares at cost as of December 31, 2024.	(81,784)		(71,731)


Total stockholders’ equity	296,939		258,817
Total liabilities and stockholders’ equity	$	421,077	$	362,381

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

THE VITA COCO COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS &

OTHER COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(Amounts in thousands, except for share and per share data)


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Net sales	$	168,759	$	144,116	$	299,680	$	255,814
Cost of goods sold	107,494		85,379		190,330		149,900
Gross profit	61,265		58,737		109,350		105,914
Operating expenses
Selling, general and administrative	36,143		28,756		64,935		56,974
Income from operations	25,122		29,981		44,415		48,940
Other income (expense)
Unrealized gain/(loss) on derivative instruments	1,067		(5,963)		3,884		(8,488)
Foreign currency gain/(loss)	482		(136)		1,062		(78)
Interest income	1,500		1,627		3,018		3,150

Other income	—		—		155		—
Total other income (expense)	3,049		(4,472)		8,119		(5,416)
Income before income taxes	28,171		25,509		52,534		43,524
Income tax expense	5,263		6,416		10,744		10,193
Net income	$	22,908	$	19,093	$	41,790	$	33,331

Other comprehensive income (loss)
Foreign currency translation adjustment	1,191		33		1,686		$	21
Total comprehensive income attributable to The Vita Coco Company, Inc.	$	24,099	$	19,126	$	43,476	$	33,352

Net income per common share
Basic	$	0.40	$	0.34	$	0.73	$	0.59
Diluted	$	0.38	$	0.32	$	0.70	$	0.57
Weighted-average number of common shares outstanding
Basic	56,795,499		56,705,220		56,894,274		56,647,393
Diluted	59,643,348		59,235,211		59,809,039		58,990,921

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

THE VITA COCO COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Amounts in thousands, except for shares)


	Common Stock			Common Stock with Exit Warrants			Total Common Stock			Additional Paid-In		Retained Earnings		Accumulated Other Comprehensive Income / (Loss)			Treasury Stock				Total Shareholders’ Equity Attributable to The Vita Coco Company, Inc.
	Shares	$ Amount		Shares	$ Amount		Shares	$ Amount		Capital						Shares		$ Amount
Balance at December 31, 2023	55,022,348	$	550	8,113,105	$	81	63,135,453	$	631	$	161,414	$	100,742	$	(649)		6,236,200		$	(59,701)	$	202,437
Net income	—	—		—	—		—	—		—		14,238		—			—		—		14,238
Purchase of treasury stock	—	—		—	—		—	—		—		—		—			391,544		(9,235)		(9,235)

Stock-based compensation	—	—		—	—		—	—		2,109		—		—			—		—		2,109
Exercise of stock awards	176,284	2		—	—		176,284	2		151		—		—			—		—		153
Foreign currency translation adjustment	—	—		—	—		—	—		—		—		(12)			—		—		(12)
Balance at March 31, 2024	55,198,632	552		8,113,105	81		63,311,737	633		163,674		114,980		(661)			6,627,744		(68,936)		209,690
Net income	—	—		—	—		—	—		—		19,093		—			—		—		19,093

Stock-based compensation	—	—		—	—		—	—		2,399		—		—			—		—		2,399
Exercise of stock awards	91,376	1		—	—		91,376	1		790		—		—			—		—		791
Foreign currency translation adjustment	—	—		—	—		—	—		—		—		33			—		—		33
Balance at June 30, 2024	55,290,008	$	553	8,113,105	$	81	63,403,113	$	634	$	166,863	$	134,073	$	(628)		6,627,744		$	(68,936)	$	232,006






Balance at December 31, 2024	55,589,282	$	556	8,113,105	$	81	63,702,387	$	637	$	174,077	$	156,694	$	(860)		6,740,446		$	(71,731)	$	258,817
Net income	—	—		—	—		—	—		—		18,882		—			—		—		18,882
Purchase of treasury stock	—	—		—	—		—	—		—		—		—			48,973		(1,501)		(1,501)

Stock-based compensation	—	—		—	—		—	—		2,186		—		—			—		—		2,186
Exercise of stock awards	105,332	1		—	—		105,332	1		(1,022)		—		—			—		—		(1,021)
Foreign currency translation adjustment	—	—		—	—		—	—		—		—		495			—		—		495
Balance at March 31, 2025	55,694,614	$	557	8,113,105	$	81	63,807,719	$	638	$	175,241	$	175,576	$	(365)		6,789,419		$	(73,232)	$	277,858

Net income	—	—		—	—		—	—		—		22,908		—			—		—		22,908
Purchase of treasury stock	—	—		—	—		—	—		—		—		—			284,728		(8,552)		(8,552)

Stock-based compensation	—	—		—	—		—	—		2,962		—		—			—		—		2,962
Exercise of stock awards	69,409	1		—	—		69,409	1		571		—		—			—		—		572
Foreign currency translation adjustment	—	—		—	—		—	—		—		—		1,191			—		—		1,191
Balance at June 30, 2025	55,764,023	$	558	8,113,105	$	81	63,877,128	$	639	$	178,774	$	198,484	$	826		7,074,147		$	(81,784)	$	296,939

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

THE VITA COCO COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Amounts in thousands)


	Six Months Ended June 30,
	2025		2024
Cash flows from operating activities:
Net income	$	41,790	$	33,331
Adjustments required to reconcile net income to cash flows from operating activities:
Depreciation and amortization	408		344
Amortization of debt issuance cost	6		—
(Gain)/loss on disposal of equipment	—		13
Bad debt expense	608		(204)
Unrealized (gain)/loss on derivative instruments	(3,884)		8,488
Stock-based compensation	5,148		4,508


Noncash lease expense	747		508

Changes in operating assets and liabilities:
Accounts receivable	(37,758)		(28,761)
Inventory	127		5,254
Prepaid expenses, net supplier advances, and other assets	(1,454)		(204)
Accounts payable, accrued expenses, and other liabilities	6,272		3,375

Net cash provided by operating activities	12,010		26,652
Cash flows from investing activities:
Cash paid for property and equipment	(1,508)		(414)

Net cash used in investing activities	(1,508)		(414)
Cash flows from financing activities:
Proceeds from exercise of stock awards	977		681




Cash paid on notes payable	(5)		(8)
Cash paid to acquire treasury stock	(10,053)		(9,235)

Net cash used in financing activities	(9,081)		(8,562)
Effects of exchange rate changes on cash and cash equivalents	961		(106)
Net increase in cash and cash equivalents	2,382		17,570
Cash, cash equivalents and restricted cash at beginning of the period (1)	165,933		132,867
Cash, cash equivalents and restricted cash at end of the period (1)	$	168,315	$	150,437

1Includes $1,273 and $334 of restricted cash as of June 30, 2025 and 2024, respectively, reported in other current assets on the condensed consolidated balance sheet.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

THE VITA COCO COMPANY, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share amounts)

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

The Vita Coco Company, Inc. and subsidiaries (the “Company”) develops, markets, and distributes various coconut water products under the brand name Vita Coco and for retailers' own brands, predominantly in the United States ("U.S."). Other products include coconut milk, coconut oil, water (under the brand name Ever & Ever), protein infused fitness drinks (under the brand name PWR LIFT), and other revenue transactions (e.g., bulk product sales). The Company completed an initial public offering (the "IPO") of its Common Stock in October 2021.

We are a public benefit corporation under Section 362 of the Delaware General Corporation Law. As a public benefit corporation, our Board of Directors (the "Board") is required by the Delaware General Corporation Law to manage or direct our business and affairs in a manner that balances the pecuniary interests of our stockholders, the best interests of those materially affected by our conduct and the specific public benefits identified in our certificate of incorporation.

The Company has ten wholly-owned subsidiaries, including four wholly-owned Asian subsidiaries established between fiscal 2012 and 2015, four North American subsidiaries established between 2012 and 2018, All Market Europe, Ltd. (“AME”) in the United Kingdom established in 2009, and one subsidiary in Germany established during 2024. Through one of its subsidiaries, the Company has a 60% joint venture interest in a company, Coco Ventures Limited, which provides for the development, marketing, distribution and branding of coconut water-based products under the Vita Coco brand in China. See Note 16, Joint Venture, for further details.

Unaudited interim financial information

The Company’s condensed consolidated interim financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and Article 10 of Regulation S-X. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the Company’s financial information for the interim period presented. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other interim period or for any other future year. The condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the fiscal year ended December 31, 2024.

During the six months ended June 30, 2025, there were no significant changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2024.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements are presented in accordance with U.S. GAAP.

Principles of Consolidation

The condensed consolidated financial statements include all the accounts of the wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors

Table of Contents

may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. Additionally, uncertainty in the macroeconomic environment resulting from current geopolitical and economic instability (including the effects of current wars and other international conflicts, as well as recently imposed tariffs) and the high interest rate and inflationary cost environment make estimates and assumptions difficult to calculate with precision. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. The most significant estimates in the condensed consolidated financial statements relate to share-based compensation, assessing long-lived assets for impairment, estimating the net realizable value of inventories, determining the accounts receivables reserve, assessing goodwill for impairment, determining the value of trade promotions, and assessing the realizability of deferred income taxes. Actual results could differ from those estimates.

Concentration of Credit Risk

The Company’s cash and accounts receivable are subject to concentrations of credit risk. The Company’s cash balances are primarily on deposit with banks in the U.S. which are guaranteed by the Federal Deposit Insurance Corporation ("FDIC") up to $250. At times, such cash may be in excess of the FDIC insurance limit. To minimize the risk, the Company’s policy is to maintain cash balances with high quality institutions, which may include banks, financial institutions and investment firms, and invest daily or reserve operating cash in money market funds, government securities, bank obligations, municipal securities or other investment vehicles with short-term maturities.

Substantially all of the Company’s customers are either wholesalers or retailers of beverages. A material default in payment, a material reduction in purchases from these or any large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company’s financial condition, results of operations and liquidity. The Company is exposed to concentration of credit risk from its major customers, for which two customers in aggregate represented 45% and 49% of total net sales for the six months ended June 30, 2025 and 2024, respectively. In addition, the two customers in aggregate also accounted for 44% and 30% of total accounts receivable as of June 30, 2025 and December 31, 2024, respectively. The Company has not experienced credit issues with these customers. Refer to Note 7, Commitments and Contingencies regarding additional information on the Company's major customers.

Recently Adopted Accounting Pronouncements

Segment Reporting

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification ("ASC") - Topic 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted the standard for the year ended December 31, 2024. The adoption of the standard did not have a material impact on the Company’s condensed consolidated statements of operations and disclosures.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which requires expenses in the consolidated statement of operations to be disaggregated into functional categories and separate significant individual expense items that are material to the understanding of the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026. In January 2025, the FASB issued ASU 2025-01, which clarified the adoption date to include interim periods with annual reporting periods after December 31, 2027. The Company is currently evaluating the impact of adopting ASU 2024-03.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes ("Topic 740"): Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires public entities, on an annual basis, to provide disclosure of specific

Table of Contents

categories in the effective tax rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting standard on its consolidated financial statements.

3. REVENUE RECOGNITION

Revenues are accounted for in accordance with ASC Topic 606, Revenue Recognition ("ASC 606"). The Company disaggregates revenue into the following product categories:

•Vita Coco Coconut Water—This product category consists of all branded coconut water product offerings under the Vita Coco labels, where the majority ingredient is coconut water. The Company determined that the sale of the products represents a distinct performance obligation as customers can benefit from purchasing the products on their own or together with other resources that are readily available to the customers. For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

•Private Label—This product category consists of all private label product offerings, which includes coconut water and oil. The Company determined the production and distribution of private label products represents a distinct performance obligation. Since there is no alternative use for these products and the Company has the right to payment for performance completed to date, the Company recognizes the revenue for the production of these private label products over time as the production for open purchase orders occurs, which may be prior to any shipment.

•Other—This product category consists of all other products, which includes Vita Coco product extensions beyond coconut water, consisting of coconut milk products, including Vita Coco Treats; Ever & Ever and PWR LIFT product offerings; Vita Coco coconut oil sold internationally; and other revenue transactions (e.g., bulk product sales). For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

The Company excludes from revenues all taxes assessed by a governmental authority that are imposed on the sale of its products and collected from customers.

The Company provides trade promotions and sales discounts to its customers and distributors. Since these sales promotions and sales discounts do not meet the criteria for a distinct good or service, they are primarily accounted for as a reduction of revenue and include payments to customers and distributors for performing activities on our behalf, such as payments for in-store displays, payments to gain distribution of new products, payments for shelf space and discounts to promote lower retail prices. These condensed consolidated financial statements include accruals for these promotions and discounts. The accruals are made for invoices that have not yet been received as of the end of the reporting period and are recorded as a reduction of sales, and are based on contract terms and our historical experience with similar programs and require management judgment with respect to estimating customer and consumer participation and performance levels.

Disaggregation of Revenue

The following table disaggregates net revenue by product type and reportable segment:

Table of Contents


	Three Months Ended June 30, 2025
	Americas		International		Consolidated
Vita Coco Coconut Water	$	120,450	$	19,882	$	140,332
Private Label	14,685		6,222		20,907
Other	6,826		694		7,520
Total	$	141,961	$	26,798	$	168,759

	Three Months Ended June 30, 2024
	Americas		International		Consolidated
Vita Coco Coconut Water	$	98,494	$	13,952	$	112,446
Private Label	23,135		4,816		27,951
Other	2,873		846		3,719
Total	$	124,502	$	19,614	$	144,116

	Six Months Ended June 30, 2025
	Americas		International		Consolidated
Vita Coco Coconut Water	$	206,568	$	33,059	$	239,627
Private Label	35,882		10,981		46,863
Other	12,111		1,079		13,190
Total	$	254,561	$	45,119	$	299,680

	Six Months Ended June 30, 2024
	Americas		International		Consolidated
Vita Coco Coconut Water	$	168,016	$	23,617	$	191,633
Private Label	47,408		9,968		57,376
Other	5,169		1,636		6,805
Total	$	220,593	$	35,221	$	255,814

4. INVENTORY

Inventory consists of the following:


	June 30, 2025		December 31, 2024
Raw materials and packaging	$	4,737	$	3,536
Finished goods	79,373		80,064
Inventory	$	84,110	$	83,600

5. GOODWILL

Goodwill consists of the following:


	June 30, 2025		December 31, 2024
Goodwill	$	7,791	$	7,791

All of the Company’s goodwill is associated with a June 2018 acquisition. The goodwill is allocated to the Americas reporting unit and is tax deductible. The Company has not recognized any impairment since the acquisition in accordance with ASC Topic 350 - Intangibles, Goodwill & Other.

Table of Contents

6. DEBT

The table below details the outstanding balances on the Company’s debt as of June 30, 2025 and December 31, 2024:


	June 30, 2025		December 31, 2024


Notes payable

Vehicle loans	8		13
	$	8	$	13
Current	8		10
Non-current	$	—	3

2020 Credit Facility

In May 2020, the Company entered into a five-year credit facility with Wells Fargo Bank, National Association consisting of a revolving line of credit, which provides for committed borrowings of $60,000 (the "2020 Credit Facility"). On February 14, 2025, the 2020 Credit Facility was amended, extending the maturity date five years to February 13, 2030. In connection with the amendment, the Company capitalized $90 of deferred financing costs, which are being amortized over the term of the facility. As of June 30, 2025, the unamortized deferred financing fees related to the revolver totaled $83 and are included in Other assets on the Company’s condensed consolidated balance sheet.

Starting in December 2022, borrowings on the 2020 Credit Facility bear interest at rates based on either: 1) a fluctuating rate per annum determined to be the sum of Daily Simple Secured Overnight Financing Rate ("SOFR") plus a spread defined in the credit agreement (the "Spread"); or 2) a fixed rate per annum determined to be the sum of the Term SOFR plus the Spread. The Spread ranges from 1.00% to 1.75%, which is based on the Company’s leverage ratio (as defined in the credit agreement) for the immediately preceding fiscal quarter as defined in the credit agreement. In addition, the Company was subject to unused commitment fees ranging from 0.10% and 0.20% on the unused amount of the line of credit in the year ended December 31, 2024, with the rate based on the Company’s leverage ratio (as defined in the 2020 Credit Facility). Starting February 14, 2025, the unused commitment fees range from 0.13% and 0.23% on the unused amount of the line of credit, with the rate being based on the Company’s leverage ratio (as defined in the 2020 Credit Facility).

As of June 30, 2025 and December 31, 2024, the Company had no outstanding balance and $60,000 undrawn and available under its amended 2020 Credit Facility. The Company incurred no interest expense for the 2020 Credit Facility for the six months ended June 30, 2025 and June 30, 2024, respectively. The unused commitment fee for the 2020 Credit Facility amounted to $19 and $15 for the three months ended June 30, 2025 and June 30, 2024, respectively. The unused commitment fee for the 2020 Credit Facility amounted to $36 and $30 for the six months ended June 30, 2025 and June 30, 2024, respectively.

The 2020 Credit Facility is collateralized by substantially all of the Company’s assets.

The 2020 Credit Facility contains certain affirmative and negative covenants that, among other things, limit the Company’s ability to, subject to various exceptions and qualifications: (i) incur liens; (ii) incur additional debt; (iii) sell, transfer or dispose of assets; (iv) merge with or acquire other companies; (v) make loans, advances or guarantees; (vi) make investments; (vii) make dividends and distributions on, or repurchases of, equity; and (viii) enter into certain transactions with affiliates. The 2020 Credit Facility also requires the Company to maintain certain financial covenants including a maximum leverage ratio, a minimum fixed charge coverage ratio, and a minimum asset coverage ratio. As of June 30, 2025, the Company was in compliance with all financial covenants.

Vehicle Loans

We periodically enter into vehicle loans. Interest rates on these vehicle loans range from 4.56% to 5.68%. The outstanding balance on the vehicle loans as of June 30, 2025 was less than $100.

Table of Contents

7. COMMITMENTS AND CONTINGENCIES

Contingencies:

Litigation—The Company may engage in various litigation matters in the ordinary course of business. The Company intends to vigorously defend itself in such matters, based upon the advice of legal counsel, and is of the opinion that the resolution of these matters will not have a material effect on the condensed consolidated financial statements. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also discloses when it is reasonably possible that a material loss may be incurred. As of June 30, 2025 and December 31, 2024, the Company has not recorded any liabilities relating to such legal matters.

Business Risk—The Company imports finished goods predominantly from manufacturers located in South American and Southeast Asian countries. The Company may be subject to certain business risks due to potential instability in these regions.

Major Customers—The Company’s customers that accounted for 10% or more of total net sales and total accounts receivable were as follows:


	Net sales				Accounts receivable
	Six Months Ended June 30,				June 30,		December 31,
	2025		2024		2025		2024
Customer A	20	%	27	%	23	%	13	%
Customer B	25	%	22	%	21	%	17	%

Net sales include branded and private label products. One of the customers acquired less than 5% ownership in the Company upon consummation of the IPO. As discussed in Note 11, Stock-Based Compensation, the same customer also was granted 200,000 restricted stock awards at the time of the IPO, of which 100,000 vested on March 31, 2023 and 100,000 vested on March 31, 2024. The customer monetized its investment in the Company during the first quarter of 2025.

Major Suppliers—The Company’s suppliers that accounted for 10% or more of the Company’s purchases were as follows:


	Six Months Ended June 30,
	2025		2024
Supplier A	15	%	22	%
Supplier B	14	%	14	%
Supplier C	13	%	8	%

8. DERIVATIVE INSTRUMENTS

The Company accounts for derivative instruments in accordance with the ASC Topic 815, Derivatives and Hedging ("ASC 815"). These principles require that all derivative instruments be recognized at fair value on each balance sheet date unless they qualify for a scope exclusion as a normal purchase or sales transaction, which is accounted for under the accrual method of accounting. In addition, these principles permit derivative instruments that qualify for hedge accounting to reflect the changes in the fair value of the derivative instruments through earnings or stockholders’ equity as other comprehensive income on a net basis until the hedged item is settled and recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative instrument’s change in fair value is immediately recognized in earnings. As of June 30, 2025 and December 31, 2024, the Company did not have any derivative instruments that it had designated as fair value or cash flow hedges.

The Company is subject to the following currency risks:

Inventory Purchases from Brazilian, Malaysian and Thai Manufacturers—In order to mitigate the currency risk on inventory purchases from its Brazilian, Malaysian and Thai manufacturers, which are settled in Brazilian real ("BRL"), Malaysian ringgit ("MYR") and Thai baht ("THB"), the Company's subsidiary, All Market Singapore Pte. Ltd. ("AMS"), enters into a series of forward currency swaps to buy BRL, MYR and THB.

Table of Contents

Intercompany Transactions Between AME and AMS—In order to mitigate the currency risk on intercompany transactions between AME and AMS, AMS enters into foreign currency swaps to sell British pounds ("GBP").

Intercompany Transactions with Canadian Customer and Vendors—In order to mitigate the currency risk on transactions with Canadian customer and vendors, the Company enters into foreign currency swaps to sell Canadian dollars ("CAD").

The notional amount and fair value of all outstanding derivative instruments in the condensed consolidated balance sheets consist of the following at:


June 30, 2025
Derivatives not designated as hedging instruments under ASC 815-20	Notional Amount		Fair Value		Balance Sheet Location
Assets
Foreign currency exchange contracts
Receive BRL/sell USD	$	27,743	$	603	Derivative assets
Receive THB/sell USD	17,352		476		Derivative assets
Receive Eur/pay USD	1,516		95		Derivative assets

Liabilities
Foreign currency exchange contracts
Receive USD/pay GBP	$	22,590	$	(1,787)	Derivative liabilities
Receive USD/pay EUR	9,245		(730)		Derivative liabilities
Receive USD/sell THB	4,582		(219)		Derivative liabilities
Receive USD/pay CAD	6,211		(66)		Derivative liabilities


December 31, 2024
Derivatives not designated as hedging instruments under ASC 815-20	Notional Amount		Fair Value		Balance Sheet Location
Assets
Foreign currency exchange contracts
Receive USD/pay EUR	$	9,060	$	458	Derivative assets
Receive USD/pay GBP	26,303		464		Derivative assets
Receive USD/pay CAD	8,486		460		Derivative assets
Liabilities
Foreign currency exchange contracts
Receive THB/sell USD	$	28,066	$	(623)	Derivative liabilities
Receive BRL/sell USD	35,443		(6,272)		Derivative liabilities

The amount and location of realized and unrealized gains and losses of the derivative instruments in the condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024 are as follows:

Table of Contents


	Three Months Ended June 30,
	2025		2024
Unrealized gain/(loss) on derivative instruments	$	1,067	$	(5,963)
Foreign currency gain/(loss)	$	(1,289)	$	188

	Six Months Ended June 30,
	2025		2024
Unrealized gain/(loss) on derivative instruments	$	3,884	$	(8,488)

Foreign currency gain/(loss)	$	(2,621)	$	795

The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC Topic 820, Fair Value Measurements ("ASC 820"). In determining fair value, the Company used a market approach and incorporates the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable internally developed inputs.

9. FAIR VALUE MEASUREMENTS

ASC 820 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observability of the inputs used in valuation techniques, the Company’s assets and liabilities are classified as follows:

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes internally developed models and methodologies utilizing significant unobservable inputs.

Forward Currency Swap Contracts—See Note 8, Derivative Instruments, for a description of these contracts. The Company’s valuation methodology for forward currency swap contracts is based upon third-party institution data.

The Company’s fair value hierarchy for those assets (liabilities) measured at fair value on a recurring basis at June 30, 2025 and December 31, 2024, is as follows:


	Level 1		Level 2		Level 3		Total
			Forward Currency Swaps/Contracts
June 30, 2025	$	—	$	(1,628)	$	—	$	(1,628)
December 31, 2024	$	—	$	(5,513)	$	—	$	(5,513)

There were no transfers between any levels of the fair value hierarchy for any of the Company’s fair value measurements.

10. STOCKHOLDERS’ EQUITY

Common and Treasury Stock—Each share of Common Stock entitles its holder to one vote on matters required to be voted on by the stockholders of the Company and to receive dividends, when and if declared by the Company’s Board.

Table of Contents

As of June 30, 2025 and December 31, 2024, the Company held 7,074,147 and 6,740,446 shares, respectively, in treasury stock. As of June 30, 2025 and December 31, 2024, the Company had 2,803,388 and 3,254,762 shares, respectively, of Common Stock available for issuance upon the conversion of outstanding equity awards under the 2021 Incentive Award Plan ("2021 Plan").

On October 30, 2023, the Company's Board approved a share repurchase program (the "Repurchase Program") authorizing the Company to repurchase up to $40,000 of Common Stock. On April 28, 2025, the Company's Board approved an additional $25,000 to the Repurchase Program, authorizing the Company to repurchase up to a total of $65,000 of the Company's Common Stock. There were no other changes made to the terms of the Repurchase Program. Shares of Common Stock may be repurchased under the Repurchase Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. To the extent not retired, shares of Common Stock repurchased under the Repurchase Program will be placed in the Company's treasury shares. The extent to which the Company repurchases shares of Common Stock, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company. The Repurchase Program has no time limits and may be suspended or discontinued at any time. The Company repurchased 284,728 shares during the three months ended June 30, 2025 at a cost of $8,552. The Company repurchased 333,701 shares under the Repurchase Program at a cost of $10,053 during the six months ended June 30, 2025. The Company repurchased 504,246 shares under the Repurchase Program at a cost of $12,030 during the year ended December 31, 2024. As of June 30, 2025, the Company had $42,143 remaining under the Repurchase Program.

11. STOCK-BASED COMPENSATION

The stockholders of the Company approved the adoption of the Company’s 2014 Stock Option and Restricted Stock Plan (the “2014 Plan”). The 2014 Plan allowed for a maximum of 8% of the sum of the Available Equity defined as the sum of: (i) the total then outstanding shares of common shares; and (ii) all available stock options (i.e., granted and outstanding stock options and stock options not yet granted). Under the terms of the 2014 Plan, the Company may grant employees, directors and consultants stock options and restricted stock awards and has the authority to establish the specific terms of each award, including exercise price, expiration and vesting. The 2014 Plan includes only outstanding stock options, all of which were granted before the Company's IPO. Generally, stock options issued pursuant to the 2014 Plan contain exercise prices no less than the fair value of Common Stock on the date of grant and have a ten-year contractual term.

In October 2021, the stockholders of the Company approved the adoption of the 2021 Incentive Award Plan ("2021 Plan"), which became effective after the closing of the IPO. On and after closing of the offering and the effectiveness of the 2021 Plan, no further grants have been made under the 2014 Plan. The maximum number of shares of our Common Stock available for issuance under the 2021 Plan is equal to the sum of: (i) 3,431,312 shares of our Common Stock; and (ii) an annual increase on the first day of each year beginning in 2022 and ending in and including 2031, equal to the lesser of (A) two percent (2%) of the outstanding shares of our Common Stock on the last day of the immediately preceding fiscal year; and (B) such lesser amount as determined by our Board; provided, however, no more than 3,431,312 shares may be issued upon the exercise of incentive stock options ("ISOs"). The 2021 Plan provides for the grant of stock options, including ISOs and nonqualified stock options ("NSOs"), dividend equivalents, stock payments, service-based restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), other incentive awards, stock appreciation rights ("SARs"), and cash awards. For the year beginning January 1, 2025, the Board elected not to increase the shares available for the 2021 Plan. As of June 30, 2025, only stock options, RSUs, and PSUs have been granted under the 2021 Plan.

For the three and six months ended June 30, 2025 and 2024, the Company recorded stock compensation costs totaling:


	Three months ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Reduction in revenue (1)	$	—	$	—	$	—	$	151
Selling, general & administrative expenses	$	2,962	$	2,399	$	5,148	$	4,357
Total stock compensation expense	$	2,962	$	2,399	$	5,148	$	4,508

(1) The cost recognized as a reduction in revenue is related to the RSUs previously granted to a major customer based on guidance in ASC 606 as stock-based sales incentive. These awards are shares of restricted Common Stock valued at $3,000

Table of Contents

granted at the time of the IPO to an entity affiliated with a significant customer, at a price per share granted at the IPO of $15.00, or 200,000 restricted shares, in connection with an amendment to extend the distributor agreement term to June 10, 2026. Since the distribution agreement had not been terminated by either party for cause as of March 31, 2023, 50% of the shares were released on March 31, 2023. The remaining 50% were released on March 31, 2024.

Option Awards with Service-based Vesting Conditions

Most of the stock option awards granted under the 2014 Plan and 2021 Plan vest based on continuous service. The options awarded to the employees have differing vesting schedules as specified in each grant agreement. The following table summarizes the service-based stock option activity during the six months ended June 30, 2025:


			Number of Stock Options

Outstanding—December 31, 2024			3,054,060
Granted			201,100
Exercised			93,831
Forfeited or expired			21,828
Outstanding—June 30, 2025			3,139,501
Exercisable—June 30, 2025			2,373,334

The fair value of the service-based stock options granted in 2025 and 2024 pursuant to the 2021 Plan was estimated on a grant or on a modification date using the Black-Scholes option-pricing model. The weighted average assumptions used in the Black-Scholes option-pricing model were as follows:


	2025		2024
Weighted average expected term	6.25 years		6.25 years
Weighted average expected volatility	31	%	32	%
Weighted average risk-free interest rate	4.10	%	4.00	%
Weighted average expected dividend yield	0	%	0	%

Option Awards with Performance and Market-based Vesting Conditions

The Company also has outstanding stock option awards containing performance-based vesting conditions, subject to achievement of various performance goals by a future period, such as revenue and Adjusted EBITDA targets. During the six months ended June 30, 2025, there was no activity related to the existing stock options with performance-based vesting conditions and no grants of stock option awards with performance-based vesting conditions.

Service-based and Performance-based Restricted Stock

RSUs were granted under the 2021 Plan and primarily vest based on continuous service. The RSUs with service-based vesting conditions awarded to the employees have differing vesting schedules as specified in each grant agreement. The RSUs granted to non-employee directors vest in full on the earlier of: (i) the day immediately preceding the date of the first Annual Shareholders Meeting following the date of grant; or (ii) the first anniversary of the date of grant. During the six months ended June 30, 2025 and June 30, 2024, the Company also granted PSUs, which are subject to achievement of

Table of Contents

various performance goals in the future, specifically net sales growth and Adjusted EBITDA targets. The following table summarizes the RSU and PSU activity for the six months ended June 30, 2025:


	Number of RSU Awards	Number of PSU Awards

Non-vested - December 31, 2024	634,803	74,579
Granted	206,506	71,140
Vested	122,983	—
Forfeited/Cancelled	17,666	1,528
Non-vested - June 30, 2025	700,660	144,191

12. INCOME TAXES

For the three months ended June 30, 2025 and 2024, the Company recorded income tax expense of $5,263 and $6,416, respectively, in its condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recorded income tax expense of $10,744 and $10,193, respectively, in its condensed consolidated statements of operations.

In assessing the recoverability of its deferred tax assets, the Company continually evaluates all available positive and negative evidence to assess the amount of deferred tax assets for which it is more likely than not to realize a benefit. For any deferred tax asset in excess of the amount for which it is more likely than not that the Company will realize a benefit, the Company establishes a valuation allowance.

As of June 30, 2025 and December 31, 2024, the Company recorded a liability of $88 and $106, respectively, for income tax uncertainties recorded in the Company's condensed consolidated balance sheet and consolidated balance sheet, respectively. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. The Company does not expect its uncertain tax positions to change significantly over the next twelve months. The Company recognized interest and penalties related to income tax uncertainties of $6 and $0, respectively, in its condensed consolidated statement of operations for the six months ended June 30, 2025 and 2024. The Company is subject to income tax examinations by the Internal Revenue Service ("IRS") and various state and local jurisdictions for the open tax years between December 31, 2019 and December 31, 2023.

On July 4, 2025, the United States enacted tax reform legislation through the passage of H.R.1, One Big Beautiful Bill Act, which changes existing U.S. tax laws, including extending or making permanent certain provisions of the 2017 Tax Cuts and Jobs Act, and repealing certain clean energy initiatives, in addition to other changes. The Company continues to evaluate the impact that the new legislation will have on the consolidated financial statements but does not anticipate a significant impact to deferred tax assets and liabilities or to income taxes payable in the period of enactment.

Table of Contents

13. EARNINGS PER SHARE

Basic and diluted earnings per share were calculated as follows:


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Numerator:

Net income	$	22,908	$	19,093	$	41,790	$	33,331
Denominator:
Weighted-average number of common shares used in earnings per share—basic	56,795,499		56,705,220		56,894,274		56,647,393
Effect of conversion of stock options	2,847,849		2,529,991		2,914,765		2,343,528
Weighted-average number of common shares used in earnings per share—diluted	59,643,348		59,235,211		59,809,039		58,990,921
Earnings per share—basic	$	0.40	$	0.34	$	0.73	$	0.59
Earnings per share—diluted	$	0.38	$	0.32	$	0.70	$	0.57

The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average number of common shares outstanding, as they would be anti-dilutive:


	Three months ended June 30,		Six months ended June 30,
	2025	2024	2025	2024
Options to purchase Common Stock and RSUs	381,471	207,168	275,595	254,490

14. SEGMENT REPORTING

The Company has two operating and reportable segments:

•Americas—The Americas segment is comprised primarily of the U.S. and Canada, and derives its revenues from the marketing and distribution of various coconut water and non-coconut water products (e.g., coconut oil and milk). The Company’s aluminum bottle canned water (Ever & Ever) and protein infused fitness drink (PWR LIFT) are marketed only in the Americas segment.

•International—The International segment is comprised primarily of Europe, the Middle East, and Asia Pacific. Asia Pacific includes the Company’s procurement arm and derives its revenues from the marketing and distribution of various coconut water and non-coconut water products, including product that is shipped directly to customers outside of Asia Pacific regions.

All intercompany transactions between the segments have been eliminated.

The Company’s CEO is the chief operating decision maker ("CODM") and manages and allocates resources between the Americas and International segments. Consistent with this decision-making process, the CODM uses financial information disaggregated between the Americas and International segment for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM evaluates segment business performance based primarily on net sales and gross profit. The CODM considers budget-to-actual variances on a monthly basis for both measures when making decisions about allocating capital and personnel to the segments and also uses segment gross profit for evaluating product pricing.

Table of Contents

Information about the Company’s operations by operating segment as of and for the three and six months ended June 30, 2025 and 2024 is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Net sales	$	168,759	$	144,116	$	299,680	$	255,814
Americas	141,961		124,502		254,561		220,593
International	26,798		19,614		45,119		35,221
Cost of goods sold	$	107,494	$	85,379	$	190,330	$	149,900
Americas	90,915		72,295		$	161,203	$	127,514
International	16,579		13,084		$	29,127	$	22,386
Gross profit	$	61,265	$	58,737	$	109,350	$	105,914
Americas	51,046		52,208		93,358		93,080
International	10,219		6,529		15,992		12,834


	As of June 30,		As of December 31,
	2025		2024
Total segment assets	$	421,077	$	362,381
Americas	278,549		241,894
International	142,528		120,487


	Three Months Ended June 30,				Six Months Ended June 30,
Reconciliation:	2025		2024		2025		2024
Total gross profit	$	61,265	$	58,737	$	109,350	$	105,914
Less:
Selling, general, and administrative expenses	36,143		28,756		64,935		56,974
Income from operations	$	25,122	$	29,981	$	44,415	$	48,940
Less:
Unrealized gain/(loss) on derivative instruments	1,067		(5,963)		3,884		(8,488)
Foreign currency gain/(loss)	482		(136)		1,062		(78)
Interest income	1,500		1,627		3,018		3,150

Other income	—		—		155		—
Income before income taxes	$	28,171	$	25,509	$	52,534	$	43,524

Table of Contents

Geographic Data:

The following table provides information related to the Company’s net sales by country, which is presented on the basis of the location that revenue from customers is recorded:


	Six Months Ended June 30,
	2025		2024
United States	$	235,813	$	205,561
United Kingdom	31,403		25,862
All other countries(1)	32,464		24,391
Net sales	$	299,680	$	255,814

___________


(1)			No individual country is greater than 10% of total net sales for the six months ended June 30, 2025 and 2024.

The following table provides information related to the Company’s property and equipment, net by country:


	June 30, 2025		December 31, 2024
Singapore	$	1,528	$	1,280
United States	$	1,163	$	758
United Kingdom	629		173
All other countries(1)	141		140
Property and equipment, net	$	3,461	$	2,351

___________


(1)			No individual country is greater than 10% of total property and equipment, net as of June 30, 2025 and December 31, 2024.

15. RELATED PARTY TRANSACTIONS

Director Nominee Agreement - On May 24, 2022, a member of the Board appointed as a nominee under the Investor Rights Agreement by Verlinvest Beverages SA ("Verlinvest"), a stockholder of the Company, entered into a nominee agreement instructing the Company to pay all cash and equity compensation earned in connection with his board of director service to Verlinvest. Based on the aforementioned nominee agreement, until the termination of the agreement, RSUs granted to this director were held by him as a nominee for Verlinvest and, upon vesting of the RSUs, the shares were transferred to Verlinvest. The nominee agreement terminated on June 3, 2025 and is no longer in effect. Following termination of the agreement, the director will receive all cash and equity compensation directly. The nominee agreement was primarily between the director and Verlinvest. The Company was a party to this arrangement solely to agree to the manner in which it would satisfy the compensation obligations to this director.

Registration Rights and Underwriting Agreements - Under the Registration Rights agreement by and among the Company, Verlinvest, and certain other investors, in connection with each demand registration, piggyback or shelf offering, the Company agreed to reimburse the holders of registrable securities for the reasonable fees and disbursements of not more than one law firm. As part of the two secondary offerings during 2023, the Company also entered into underwriting agreements, to which Verlinvest was a party. In connection with the secondary share offering by Verlinvest in May 2023, Verlinvest agreed to waive its right to reimbursement of legal fees for its counsel in the fourth quarter of 2023, and those expenses, in the amount of $140, were not reimbursed by the Company. In connection with the secondary share offering by Verlinvest in November 2023, in April 2024, Verlinvest agreed to waive its right to reimbursement of legal fees for its counsel, and those expenses, in the amount of $324, were not reimbursed by the Company.

Table of Contents

16. INVESTMENT IN UNCONSOLIDATED JOINT VENTURE

In accordance with ASC 323, Investments - Equity Method and Joint Ventures, investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of earnings or losses reported in the condensed consolidated statements of operations.

Through one of its subsidiaries, the Company has a 60% joint venture interest in a company, Coco Ventures Limited, which provides for the development, marketing, distribution and branding of coconut water-based products under the Vita Coco brand in China. Coco Ventures Limited purchases coconut water products from the Company. The Company acquired this interest on August 2, 2024, the date on which the Company obtained significant influence, for $585 to be paid in cash within one year. The Company recorded the initial investment in the joint venture upon cash payment. Since the Company is deemed not to have a controlling interest in Coco Ventures Limited, the Company’s investment is accounted using the equity method of accounting in accordance with ASC 323. In the six months ended June 30, 2025, the Company contributed $104 as a part of initial capital funding. Coco Ventures Limited commenced operations in February 2025.

17. LEASES

In August 2024, the Company signed a lease agreement for a new office in New York, New York. The Company's existing New York office lease expired on April 30, 2025, and was extended to October 31, 2025 to allow for a smooth transition to the Company's new New York office. The operating lease commenced on January 1, 2025, ending in December 2034, with an option to extend for an additional two years. The Company recognized right-of-use assets and lease liabilities of $10,002 and $11,692, respectively, upon lease commencement on the Company’s condensed consolidated balance sheet. Additionally, upon signing the agreement, the Company was required to establish a letter of credit of $920 as a security deposit which may be used in case of delinquency, which is accounted for as restricted cash. In addition, in November 2024, the Company signed a lease agreement for a new office in London, United Kingdom. The operating lease commenced on January 2, 2025 and terminates in December 2030. The Company recognized right-of-use assets and lease liabilities of $1,140 and $1,252 respectively, upon lease commencement on the Company’s condensed consolidated balance sheet. In April 2025, the Company signed an agreement for a new office in Singapore. The operating lease commenced on April 1, 2025 and terminates in June 2030. The Company recognized right-of-use assets and lease liabilities of $1,564 and $1,564 respectively, upon lease commencement on the Company’s condensed consolidated balance sheet.

The following table summarizes supplemental balance sheet information for the Company’s operating leases:


	Line Item in Balance Sheet	As of June 30, 2025		As of December 31, 2024
Operating lease right-of-use assets	Right-of-use assets	$	12,222	$	385
Current portion of operating lease liabilities	Accrued expenses and other current liabilities	$	769	$	422
Non-current portion of operating lease liabilities	Operating lease liabilities, long-term	$	13,996	$	—

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and filed with the Securities and Exchange Commission ("SEC") on February 26, 2025 (the “Form 10-K”). This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part I, Item 1A, “Risk Factors” of the Form 10-K and other factors set forth in the Form 10-K and Quarterly Reports on Form 10-Q.

Overview

The Vita Coco Company pioneered packaged coconut water in 2004 and we have extended our business into other categories. Our mission is to deliver great tasting, natural and nutritious products that we believe are better for consumers and better for the world. We are one of the largest brands globally in the coconut and other plant waters category, and a large supplier of private label coconut water.

Our branded portfolio is led by our Vita Coco brand, which is the leader in the coconut water category in the United States, and also includes coconut oil, juice, and milk offerings. Our other brands include Ever & Ever, a sustainably packaged water, and PWR LIFT, a protein-infused fitness drink. We also previously offered Runa, a plant-based energy drink inspired by the guayusa plant native to Ecuador, which we ceased selling in December 2023. We supply private label products to key retailers in both the coconut water and coconut oil categories. Additionally, we generate revenue from bulk product sales to beverage and food companies.

As of June 30, 2025, we source our coconut water from a diversified global network of 16 factories across six countries supported by thousands of coconut farmers. As we do not own any of these factories, our supply chain is a fixed asset-lite model designed to better react to changes in the market or consumer preferences. We also work with co-packers in U.S., Canada, Mexico, and Europe to support local packaging and repacking of our products to better service our customers’ needs.

Vita Coco is available in over 35 countries, with our primary markets located in North America, the United Kingdom and Germany. Our primary markets for private label are North America and Europe. Our products are distributed primarily through club, food, drug, mass, convenience, e-commerce and food service channels. Our products are also available in a variety of on-premise locations such as corporate offices, fitness clubs, airports and educational institutions.

Key Factors Affecting Our Performance

We believe that our performance and future success depend on a number of factors that present significant opportunities for us. There have been no material changes to such factors from those described in the Form 10-K under the heading “Key Factors Affecting our Performance” and the changes noted below. Those factors also pose risks and challenges, including those discussed in Part I, Item 1A. “Risk Factors” of the Form 10-K.

•Uncertainty in the macroeconomic environment resulting from geopolitical and economic instability (including the effects of current wars and other international conflicts) and variability in interest rates, foreign exchange rates, tariffs and other import related fees, and inflationary cost environments may affect our global supply chain. Additionally, as further discussed below, the extent and duration of tariffs imposed by the U.S. government on other countries and reciprocal tariffs placed on U.S. goods in response thereto remains uncertain and may depend on various factors, including negotiations and relationships between the U.S. and affected countries, tariff exemptions, negative sentiment toward U.S. companies and products, and availability of domestic alternatives in our supply chain. It is not currently possible to ascertain the overall impact of these macroeconomic uncertainties on our business, results of operations, financial condition or liquidity. Future events and effects related to these macroeconomic uncertainties cannot be determined with precision and actual results could significantly differ from estimates or forecasts. For a further discussion of the risks and challenges posed by these events, please see Part I, Item 1A. “Risk Factors” of the Form 10-K.

•During the first quarter of 2025, the U.S. government announced tariffs on certain imports, including imports from Mexico, and Canada. We currently believe that our production in Mexico and Canada is exempt from these tariffs under the United States-Mexico-Canada Agreement ("USMCA"). On April 2, 2025, the U.S. announced a new

Table of Contents

universal baseline tariff of 10%, plus significant additional country-specific tariffs for select trading partners, on all U.S. imports. The reciprocal tariffs were subsequently paused for 90 days on most countries; however the 10% baseline tariff is currently being applied, which has increased our cost of goods sold. The baseline tariffs are being challenged in the U.S. legal system and it is unclear whether the tariffs will be upheld and remain in place, or if they will be struck down by the courts. Currently, we are assuming for purposes of our business operations that the baseline tariffs will be in effect indefinitely. However, the uncertainty around the long-term tariff rates that could be applied to our importation of products into the U.S. presents significant challenges to our operations and supply chain, and may result in future results being significantly different than any outlook given. We cannot predict what additional actions might be considered or implemented by the U.S. or its trade partners, particularly in the current geopolitical environment. The uncertainty could also cause disturbances in ocean shipping capacity that could affect our ability to secure ocean freight containers for our products, and create inflationary effects on our costs, in addition to the direct impact of tariffs. We are closely monitoring the evolving tariff landscape and attempting to mitigate these impacts, including using pricing adjustments, sourcing strategies and other cost-mitigation measures. However, there can be no assurance that we will be able to fully mitigate the impacts of such tariffs or that the imposition of tariffs, and the resulting economic impact on the U.S. market and consumer, will not be material to our financial results. We primarily source from the Philippines and Brazil, with additional sourcing from Sri Lanka, Thailand, Malaysia, Vietnam, Canada, and Mexico. Recently, the administration delayed the reciprocal tariff implementation, but then announced significant proposed tariffs on certain of these countries replacing the initially announced reciprocal tariffs, which may further increase our cost of goods sold. In particular, a 50% tariff has been proposed for Brazil, which was not initially listed as one of the proposed reciprocal tariffs. At this time, the overall impact on our business related to tariffs remains uncertain and depends on multiple factors, including the timing, duration and size of any tariffs, future changes to tariff rates, scope, or enforcement of such tariffs, reciprocal measures by impacted trade partners, inflationary effects, changes to consumer purchasing behavior, and the effectiveness of our responses in managing these challenges. These tariff actions, retaliatory measures, or other trade restrictions, could materially and adversely affect our business.

•Our sales to one of our major customers include branded and private label product. As discussed in our Form 10-K, the private label coconut oil business with this customer discontinued in early 2024 and we expect private label coconut water net sales in 2025 with this customer to be impacted by the loss of some regions, which started primarily in the second quarter of 2025.

Components of Our Results of Operations

Net Sales

We generate revenue through the sale of our Vita Coco branded coconut water, Private Label, and Other products in the Americas and International segments. Our sales are predominantly made to distributors or to retailers for final sale to consumers through retail channels, which includes sales to traditional brick and mortar retailers, who may also resell our products through their own online platforms. Our revenue is recognized net of allowances for returns, discounts, credits, and any taxes collected from consumers.

We provide trade promotions and sales discounts to its customers and distributors. Since these sales promotions and sales discounts do not meet the criteria for a distinct good or service, they are primarily accounted for as a reduction of revenue and include payments to customers and distributors for performing activities on our behalf, such as payments for in-store displays, payments to gain distribution of new products, payments for shelf space and discounts to promote lower retail prices. The accompanying condensed consolidated financial statements include accruals for these promotions and discounts. The accruals are made for invoices that have not yet been received as of the end of the reporting period and are recorded as a reduction of sales, and are based on contract terms and our historical experience with similar programs and require management judgment with respect to estimating customer and consumer participation and performance levels.

Cost of Goods Sold

Cost of goods sold includes the costs of the products sold to customers, inbound and outbound shipping and handling costs, freight and duties, shipping and packaging supplies, and warehouse fulfillment costs.

Table of Contents

Gross Profit and Gross Margin

Gross profit is net sales less cost of goods sold, and gross margin is gross profit as a percentage of net sales. Gross profit has been, and will continue to be, affected by various factors, including the mix of products we sell, the channels through which we sell our products, the promotional environment in the marketplace, manufacturing costs, commodity prices, warehouse costs, and transportation rates. We expect that our gross margin will fluctuate from period to period depending on the interplay of these variables.

Management believes gross margin provides investors with useful information related to the profitability of our business prior to considering the operating costs incurred. Management uses gross profit and gross margin as key measures in making financial, operating, and planning decisions and in evaluating our performance.

Operating Expenses

Selling, General and Administrative Expenses

Selling, general and administrative expenses ("SG&A") include marketing expenses, promotional expenses, and general and administrative expenses. Marketing and promotional expenses consist primarily of costs incurred promoting and marketing our products and are primarily driven by investments to grow our business and retain customers. General and administrative expenses include payroll, employee benefits, stock-based compensation, broker commissions and other headcount-related expenses associated with supply chain & operations, finance, information technology, human resources and other administrative-related personnel, as well as general overhead costs of the business, including research and development for new innovations, rent and related facilities and maintenance costs, depreciation and amortization, and legal, accounting, and professional fees.

Other Income (Expense), Net

Unrealized Gain/(Loss) on Derivative Instruments

We are subject to foreign currency risks as a result of our inventory purchases and intercompany transactions. In order to mitigate the foreign currency risks, we and our subsidiaries enter into foreign currency exchange contracts which are recorded at fair value. Unrealized gain/(loss) on derivative instruments consists of gains or losses on such foreign currency exchange contracts which are unsettled as of period end. See Part I, Item 3 “Quantitative and Qualitative Disclosures about Market Risk—Foreign Currency Exchange Risk” for further information.

Foreign Currency Gain/(Loss)

Our reporting currency is the U.S. dollar. We maintain the financial statements of each entity within the group in its local currency, which is also the entity’s functional currency. Foreign currency gain/(loss) represents the transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency. See “—Quantitative and Qualitative Disclosures about Market Risk—Foreign Currency Exchange Risk” for further information.

Interest Income

Interest income consists of interest income earned on our cash and cash equivalents, and money market funds.

Income Tax Expense

We are subject to federal and state income taxes in the United States and taxes in foreign jurisdictions in which we operate. We recognize deferred tax assets and liabilities based on temporary differences between the financial reporting and income tax bases of assets and liabilities using statutory rates. We regularly assess the need to record a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Operating Segments

We operate in two reporting segments:

•Americas—The Americas segment is comprised of our operations in the Americas region, primarily in the United States and Canada.

Table of Contents

•International—The International segment is comprised of our operations primarily in Europe, the Middle East, and the Asia Pacific regions, which includes the Company’s procurement arm.

Each segment derives its revenues from the following product categories:

•Vita Coco Coconut Water—This product category consists of all branded coconut water product offerings under the Vita Coco labels, where the majority ingredient is coconut water. For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

•Private Label —This product category consists of all private label product offerings, which includes coconut water and coconut oil. The Company determined the production and distribution of private label products represents a distinct performance obligation. Since there is no alternative use for these products and the Company has the right to payment for performance completed to date, the Company recognizes the revenue for the production of these private label products over time as the production for open purchase orders occurs, which may be prior to any shipment.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations for the three and six months ended June 30, 2025 and 2024, respectively:


(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Net sales	$	168,759	$	144,116	$	299,680	$	255,814
Cost of goods sold	107,494		85,379		190,330		149,900
Gross profit	61,265		58,737		109,350		105,914
Operating expenses
Selling, general, and administrative	36,143		28,756		64,935		56,974
Income from operations	25,122		29,981		44,415		48,940
Other income (expense)
Unrealized gain/(loss) on derivative instrument	1,067		(5,963)		3,884		(8,488)
Foreign currency gain/(loss)	482		(136)		1,062		(78)
Interest income	1,500		1,627		3,018		3,150

Other income	—		—		155		—
Total other income (expense)	3,049		(4,472)		8,119		(5,416)
Income before income taxes	28,171		25,509		52,534		43,524
Income tax expense	5,263		6,416		10,744		10,193
Net income	$	22,908	$	19,093	$	41,790	$	33,331

Table of Contents

Net Sales

The following table provides a comparative summary of net sales by operating segment and product category:


(in thousands)	Three Months Ended June 30,				Change				Six Months Ended June 30,				Change
	2025		2024		Amount		Percentage		2025		2024		Amount		Percentage
Americas segment
Vita Coco Coconut Water	$	120,450	$	98,494	$	21,956	22.3	%	$	206,568	$	168,016	$	38,552	22.9	%
Private Label	14,685		23,135		(8,450)		(36.5)	%	35,882		47,408		(11,526)		(24.3)	%
Other	6,826		2,873		3,953		137.6	%	12,111		5,169		6,942		134.3	%
Subtotal	$	141,961	$	124,502	$	17,459	14.0	%	$	254,561	$	220,593	$	33,968	15.4	%
International segment
Vita Coco Coconut Water	$	19,882	$	13,952	$	5,930	42.5	%	33,059		23,617		$	9,442	40.0	%
Private Label	6,222		4,816		1,406		29.2	%	10,981		9,968		1,013		10.2	%
Other	694		846		(152)		(18.0)	%	1,079		1,636		(557)		(34.0)	%
Subtotal	$	26,798	$	19,614	$	7,184	36.6	%	$	45,119	$	35,221	$	9,898	28.1	%
Total net sales	$	168,759	$	144,116	$	24,643	17.1	%	$	299,680	$	255,814	$	43,866	17.1	%

For the three months ended June 30, 2025, the primary driver of the consolidated net sales increase of 17.1% was strong Vita Coco Coconut Water volume growth. Vita Coco Coconut Water net sales increased 24.8%, with a case equivalents ("CE") volume increase of 20.9% and growth in the Other category, driven by the U.S. rollout of Vita Coco Treats. This was partially offset by a 25.2% decrease in private label net sales, which was due largely to the loss of private label coconut water service regions for multiple customers that started in the first six months of 2025. For the six months ended June 30, 2025, the consolidated net sales increase of 17.1% was driven by Vita Coco Coconut Water, which had a 25.0% net sales increase, with a case equivalents CE volume increase of 22.7%. This was partially offset by private label net sales decline of 18.3% resulting from the loss of private label coconut water service regions for multiple customers in addition to the transition out of private label coconut oil sales to a major customer that began in the first quarter of 2024.

Volume in Case Equivalents

The following table provides a comparative summary of the percentage change in our volume in CE for the three and six months ended June 30, 2025 compared to the three and six months ended June 30, 2024, by operating segment and product category:


	Percentage Change - Three Months Ended June 30, 2025 vs. 2024
	Americas		International		Total
Vita Coco Coconut Water	20.6	%	22.9	%	20.9	%
Private Label	(34.0)	%	26.5	%	(21.7)	%
Other	212.7	%	54.2	%	202.2	%
Total volume (CE)	12.2	%	24.1	%	14.1	%

	Percentage Change - Six Months Ended June 30, 2025 vs. 2024
	Americas		International		Total
Vita Coco Coconut Water	21.7	%	27.7	%	22.7	%
Private Label	(18.5)	%	20.3	%	(10.8)	%
Other	202.0	%	27.0	%	189.3	%
Total volume (CE)	15.2	%	25.4	%	16.9	%

Note: A CE is a standard volume measure used by management, which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil.

Table of Contents

*International, Other excludes minor volume that is treated as zero CE.

Americas Segment

Americas net sales increased $17.5 million, or 14.0%, to $142.0 million for the three months ended June 30, 2025 from $124.5 million for the three months ended June 30, 2024. The increase was primarily driven by CE volume growth of 20.6% of Vita Coco Coconut Water, partially offset by volume lost due to the loss of private label coconut water service regions for several customers that started in the first six months 2025. Americas net sales increased $34.0 million, or 15.4%, to $254.6 million for the six months ended June 30, 2025 from $220.6 million for the six months ended June 30, 2024. The increase was primarily driven by CE volume growth of 21.7% of Vita Coco Coconut Water, offset by the private label decline.

Vita Coco Coconut Water net sales increased $22.0 million, or 22.3%, to $120.5 million for the three months ended June 30, 2025, from $98.5 million for the three months ended June 30, 2024. The increase was the result of CE volume growth of 20.6% due to increased demand. Vita Coco Coconut Water net sales increased $38.6 million, or 22.9%, to $206.6 million for the six months ended June 30, 2025, from $168.0 million for the six months ended June 30, 2024. The increase was the result of CE volume growth of 21.7% due to strong consumer demand.

Private label net sales decreased $8.5 million, or 36.5%, to $14.7 million for the three months ended June 30, 2025, from $23.1 million for the three months ended June 30, 2024, due to a decrease in the private label business as outlined above, resulting in CE volume decrease of 34.0%. Private label net sales decreased $11.5 million, or 24.3%, to $35.9 million for the six months ended June 30, 2025, from $47.4 million for the six months ended June 30, 2024. The decrease was the result of CE volume decline of 18.5% due to the aforementioned losses of private label coconut oil and coconut water business.

Net sales from Other products increased by $4.0 million, or 137.6%, to $6.8 million for the three months ended June 30, 2025 from $2.9 million for the three months ended June 30, 2024, primarily due to the national rollout of Vita Coco Treats in the U.S. Net sales from Other products increased by $6.9 million, or 134.3%, to $12.1 million for the six months ended June 30, 2025 from $5.2 million for the six months ended June 30, 2024, driven by CE volume increase of 202.0%, driven by the rollout of Vita Coco Treats.

International Segment

International net sales increased by $7.2 million, or 36.6%, to $26.8 million for the three months ended June 30, 2025, from $19.6 million for the three months ended June 30, 2024. The increase of 24.1% in CE volume is primarily driven by growth in Germany and the United Kingdom, partially offset by softness in China. International net sales increased by $9.9 million, or 28.1%, to $45.1 million for the six months ended June 30, 2025, from $35.2 million for the six months ended June 30, 2024. The increase is primarily driven by CE volume growth of 25.4% in Germany and United Kingdom partially offset by softness in China.

Vita Coco Coconut Water net sales increased by $5.9 million, or 42.5%, to $19.9 million for the three months ended June 30, 2025, from $14.0 million for the three months ended June 30, 2024. The increase was driven by higher volume in Europe due to strong demand for our products, along with some pricing and foreign exchange rate benefits. Vita Coco Coconut Water net sales increased by $9.4 million, or 40.0%, to $33.1 million for the six months ended June 30, 2025, from $23.6 million for the six months ended June 30, 2024. The increase was primarily driven by strong CE volume growth in Europe coupled with pricing benefits.

Private label net sales increased $1.4 million, or 29.2%, to $6.2 million for the three months ended June 30, 2025 from $4.8 million for the three months ended June 30, 2024. The increase was driven primarily by private label coconut water CE volume growth in Europe, which was partially offset by a decrease in the private label coconut oil business in Asia. Private label net sales increased $1.0 million, or 10.2%, to $11.0 million for the six months ended June 30, 2025 from $10.0 million for the six months ended June 30, 2024. The increase was driven primarily by CE volume growth in Europe private label coconut water sales, partially offset by a decrease in private label coconut oil volume.

Net sales from Other products decreased 18.0% and 34.0% for the three and six months ended June 30, 2025, respectively, compared to the same periods in the prior year, primarily driven by the decrease in sales of Vita Coco coconut oil.

Table of Contents

Gross Profit


($ in thousands)	Three Months Ended June 30,						Change				Six Months Ended June 30,						Change
	2025			2024			Amount		Percentage		2025			2024			Amount		Percentage
Cost of goods sold
Americas segment	$	90,915		$	72,295		$	18,620	25.8	%	$	161,203		$	127,514		$	33,689	26.4	%
International segment	16,579			13,084			3,495		26.7	%	29,127			22,386			6,741		30.1	%
Total cost of goods sold	$	107,494		$	85,379		$	22,115	25.9	%	$	190,330		$	149,900		$	40,430	27.0	%
Gross profit
Americas segment	$	51,046		$	52,208		$	(1,162)	(2.2)	%	$	93,358		$	93,080		$	278	0.3	%
International segment	10,219			6,529			3,690		56.5	%	15,992			12,834			3,158		24.6	%
Total gross profit	$	61,265		$	58,737		$	2,528	4.3	%	$	109,350		$	105,914		$	3,436	3.2	%
Gross margin
Americas segment	36.0		%	41.9		%			(5.9)	%	36.7		%	42.2		%			(5.5)	%
International segment	38.1		%	33.3		%			4.8	%	35.4		%	36.4		%			(1.0)	%
Consolidated	36.3		%	40.8		%			(4.5)	%	36.5		%	41.4		%			(4.9)	%

On a consolidated basis, cost of goods sold increased $22.1 million, or 25.9%, to $107.5 million for the three months ended June 30, 2025, from $85.4 million for the three months ended June 30, 2024. On a consolidated and segment basis, the increase was primarily driven by higher CE volume and higher rates for finished goods and transportation costs and the initial impact of baseline tariffs. Cost of goods sold increased by $40.4 million, or 27.0%, to $190.3 million for the six months ended June 30, 2025, from $149.9 million for the six months ended June 30, 2024. On a consolidated basis, the increase was primarily related to increased CE volume and higher finished goods and transportation costs, and to a lesser extent, the initial impact of baseline tariffs.

For the three months ended June 30, 2025, consolidated gross profit increased $2.5 million, or 4.3%, to $61.3 million, from $58.7 million for the three months ended June 30, 2024, primarily driven by higher CE volume. The increase was partially offset by increased rates for finished goods and transportation costs and the initial impact of baseline tariffs, these costs also resulted in gross margin decline, which was partially offset by branded coconut water pricing and favorable product mix. For the six months ended June 30, 2025, consolidated gross profit increased $3.4 million, or 3.2%, to $109.4 million, from $105.9 million for the six months ended June 30, 2024, also primarily driven by higher CE volume, and partially offset by increased rates for finished goods and transportation costs and the initial impact of baseline tariffs. Similar to the quarterly results, higher year-on-year ocean freight and finished goods costs resulted in a decrease in gross margin, partially offset by branded coconut water pricing and favorable product mix.

Operating Expenses


($ in thousands)	Three Months Ended June 30,				Change				Six Months Ended June 30,		Change
	2025		2024		Amount		Percentage		2025	2024	Amount	Percentage
Selling, general, and administrative	$	36,143	$	28,756	$	7,387	25.7	%	64,935	56,974	7,961	14.0	%

Selling, General and Administrative Expenses

For the three months ended June 30, 2025, SG&A increased $7.4 million, or 25.7%, versus the three months ended June 30, 2024. The increase was primarily driven by an increase of $3.1 million in marketing expense primarily due to new product awareness campaigns for Vita Coco Treats, $2.7 million in personnel-related expenses, $0.9 million in higher reserves for bad debt, and $0.4 million related to an overlap of rent expense for the new New York office with the current New York office. During the six months ended June 30, 2025, SG&A increased $8.0 million, or 14.0%, versus the six months ended June 30, 2024. The increase was primarily driven by an increase of $4.6 million in personnel-related expenses and $3.0 million in marketing expense due to new product awareness campaigns for Vita Coco Treats, $0.8 million of higher reserves for bad debt expenses, $0.7 million related to the overlap of rent expense for the new New York office with the current New York office. The increases were partially offset by a reduction of $2.3 million in sales related expenses.

Table of Contents

Other Income (Expense), Net


($ in thousands)	Three Months Ended June 30,				Change				Six Months Ended June 30,				Change
	2025		2024		Amount		Percentage		2025		2024		Amount		Percentage
Unrealized gain/(loss) on derivative instruments	$	1,067	$	(5,963)	$	7,030	n/m		$	3,884	$	(8,488)	$	12,372	n/m
Foreign currency gain/(loss)	482		(136)		618		n/m		1,062		(78)		1,140		n/m
Interest income	1,500		1,627		(127)		(7.8	%)	3,018		3,150		(132)		(4.2	%)

Other income	—		—		—		n/m		155		—		155		n/m
	$	3,049	$	(4,472)	$	7,521	n/m		$	8,119	$	(5,416)	$	13,535	n/m

Unrealized Gain/(Loss) on Derivative Instruments

For the three months ended June 30, 2025 and 2024, we recorded gains of $1.1 million and losses of $6.0 million, respectively, for the mark-to-market changes in fair value on the outstanding derivative instruments for forward foreign currency exchange contracts, with the largest gain for the three months ended June 30, 2025 related to the contracts hedging the BRL and THB. For the six months ended June 30, 2025 and 2024, we recorded gains of $3.9 million and losses of $8.5 million, respectively, for the mark-to-market changes in fair value on the outstanding derivative instruments for forward foreign currency exchange contracts, with the largest gain for the six months ended June 30, 2025 related to the contracts hedging the BRL and THB, partially offset by loss on GBP, CAD, and EUR hedges.

Foreign Currency Gain/(Loss)

For the three months ended June 30, 2025, the change in foreign currency gain was $0.6 million as compared to June 30, 2024. For the six months ended June 30, 2025, the change in foreign currency gain was $1.1 million as compared to June 30, 2024. The change in all periods was a result of movements in various foreign currency exchange rates related to transactions denominated in currencies other than the functional currency. See "Quantitative and Qualitative Disclosures about Market Risk - Foreign Currency Exchange Risk" for further information.

Interest Income

For the three months ended June 30, 2025, interest income decreased $0.1 million compared to June 30, 2024 primarily due to lower interest rates in the 2025 period compared to the 2024 period. For the six months ended June 30, 2025, interest income decreased $0.1 million as compared to June 30, 2024. The decrease in interest income was due to lower interest rates compared to prior year.

Other Income

For the six months ended June 30, 2025, Other income of $0.2 million is due to the sale of intellectual property.

Income Tax Expense


($ in thousands)	Three Months Ended June 30,				Change				Six Months Ended June 30,						Change
	2025		2024		Amount		Percentage		2025			2024			Amount		Percentage
Income tax expense	5,263		6,416		$	(1,153)	(18.0)	%	$	10,744		$	10,193		$	551	5.4	%
Tax rate	18.7	%	25.2	%					20.5		%	23.4		%

Our quarterly income tax provision is based on an estimated annual effective tax rate applied to our consolidated year-to-date pre-tax income or loss. The effective income tax rate is based upon the estimated income for the year, the composition of that income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.

Table of Contents

For the six months ended June 30, 2025 and 2024, our effective tax rate was 20.5% and 23.4%, respectively. The effective tax rate for the current period is lower than the U.S. statutory rate of 21% primarily as a result of discrete items recorded during the period. The effective tax rate for the period ending June 30, 2024 was higher than the U.S. statutory rate of 21% primarily as a result of state income taxes for the U.S. entity. The change in effective tax rates between the periods is primarily driven by the jurisdictional mix of the Company’s pre-tax profits and the relative impact of other non-deductible expenses in relation to the pre-tax profits.

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA are supplemental non-GAAP financial measures that are used by management and external users of our financial statements, such as industry analysts, investors and lenders. These non-GAAP measures should not be considered as alternatives to net income as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP and should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

These non-GAAP measures are a key metric used by management and our Board to assess our financial performance. We present these non-GAAP measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company.

We define EBITDA as net income before interest, taxes, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA with adjustments to eliminate the impact of certain items, including certain non-cash and other items, that we do not consider representative of our ongoing operating performance.

A reconciliation from net income to EBITDA and Adjusted EBITDA is set forth below:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025	2024
	(in thousands)				(in thousands)
Net income	22,908		19,093		41,790	33,331
Depreciation and amortization	206		182		408	344
Interest income	(1,500)		(1,627)		(3,018)	(3,150)

Income tax expense	5,263		6,416		10,744	10,193

EBITDA	26,877		24,064		49,924	40,718
Stock-based compensation (a)	2,962		2,399		5,148	4,508
Unrealized (gain)/loss on derivative instruments (b)	(1,067)		5,963		(3,884)	8,488
Foreign currency (gain)/loss (b)	(482)		136		(1,062)	78
Secondary Offering Costs (c)	—		(324)		—	(324)
Other adjustments (d)	952		—		1,621	—
Adjusted EBITDA	$	29,242	$	32,238	51,747	$	53,468

____________

(a)Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.

(b)Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.

(c)The amounts for the three and six months ended June 30, 2024 relate to an expense waiver of certain costs incurred during the November 9, 2023 block trade. The Company did not receive any proceeds from the sale of the shares. For additional information regarding the expense waiver for the three and six months ended June 30, 2024, see Note 15, Related Party Transactions, in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

(d)The three months ended June 30, 2025 includes $0.6 million related to a one-time 2023 incentive program that is measured based on full-year 2025 performance structured differently from our other ongoing employee incentive

Table of Contents

programs, and $0.4 million of rent expense related to our new New York City office that overlap with our current New York City office rent charges. The six months ended June 30, 2025 includes $1.2 million related to a one-time 2023 incentive program that is measured based on full-year 2025 performance structured differently from our other ongoing employee incentive programs, and $0.7 million of dual rent expense related to our New York City office. These amounts were offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a gain of $0.2 million from a sale of intellectual property.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through cash generated from our business operations and proceeds on borrowings through our credit facilities and term loans. We had $167.0 million and $164.7 million of cash and cash equivalents as of June 30, 2025 and December 31, 2024, respectively. From time to time, we may supplement our liquidity needs with incremental borrowing capacity under the 2020 Credit Facility.

Considering recent market conditions and our business assumptions, we have reevaluated our operating cash flows and cash requirements and believe that current cash, cash equivalents, future cash flows from operating activities and cash available under our 2020 Credit Facility will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the condensed consolidated financial statements included herein and the foreseeable future.

Our future capital requirements will depend on many factors, including our revenue growth rate, our working capital needs primarily for inventory build, our global footprint, the expansion of our marketing activities, the timing and extent of spending to support product development efforts, the introduction of new and enhanced products and the continued market consumption of our products, as well as any shareholder distribution either through equity buybacks or dividends. Our asset-lite operating model has historically provided us with a low cost, nimble, and scalable supply chain, which allows us to adapt to changes in the market or consumer preferences while also efficiently introducing new products across our platform. We may seek additional equity or debt financing in the future in order to acquire or invest in complementary businesses, products and/or new IT infrastructures. In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to expand our operations and invest in continued product innovation, we may not be able to compete successfully, which would harm our business, operations and financial condition.

Cash Flows

The following tables summarize our sources and uses of cash:


	Six Months Ended June 30,				Change
	2025		2024		Amount		Percentage
($ in thousands)
Cash flows provided by (used in):
Operating activities	$	12,010	$	26,652	$	(14,642)	(54.9	%)
Investing activities	(1,508)		(414)		(1,094)		n/m
Financing activities	(9,081)		(8,562)		(519)		6.1	%
Effects of exchange rate changes on cash and cash equivalents	961		(106)		1,067		n/m
Net (decrease)/increase in cash and cash equivalents	$	2,382	$	17,570	$	(15,188)	86.4	%

Operating Activities

Our main source of operating cash is payments received from our customers. Our primary use of cash in operating activities are for cost of goods sold and SG&A expenses.

During the six months ended June 30, 2025, cash provided by operating activities decreased $14.6 million compared to the six months ended June 30, 2024. The decrease is driven by timing differences in the collection of accounts receivable and payments made and higher inventory purchases, partly offset by increase in net income, net of non-cash adjustments.

Table of Contents

Investing Activities

During the six months ended June 30, 2025, cash used in investing activities was $1.5 million as compared to $0.4 million for the six months ended June 30, 2024. The increase was primarily due to capital expenditures related to the new New York, London and Singapore offices.

Financing Activities

During the six months ended June 30, 2025 compared to the six months ended June 30, 2024, net cash used by financing activities increased by $0.5 million, primarily driven by higher volume of share repurchases in the six months ended June 30, 2025 compared to the prior year period. See Note 10, Stockholders' Equity, in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, for further discussion on share repurchases.

Debt

We had an immaterial amount of debt outstanding as of June 30, 2025 and December 31, 2024, which was related to vehicle loans.

Revolving Credit Facility

In May 2020, the Company entered into the 2020 Credit Facility, which currently provides for committed borrowings of $60 million. On February 14, 2025, the 2020 Credit Facility was amended, extending the maturity five years to February 13, 2030.

Starting in December 2022, borrowings on the 2020 Credit Facility bear interest at rates based on either: 1) a fluctuating rate per annum determined to be the sum of Daily Simple SOFR plus the Spread; or 2) a fixed rate per annum determined to be the sum of the Term SOFR plus the Spread. The Spread ranges from 1.00% to 1.75%, which is based on the Company’s leverage ratio (as defined in the credit agreement) for the immediately preceding fiscal quarter as defined in the credit agreement. In addition, the Company was subject to unused commitment fees ranging from 0.10% and 0.20% on the unused amount of the line of credit in the year ended December 31, 2024, with the rate based on the Company’s leverage ratio (as defined in the credit agreement). As of February 14, 2025, the unused commitment fees range from 0.13% and 0.23% on the unused amount of the line of credit, with the rate being based on the Company’s leverage ratio (as defined in the credit agreement).

The outstanding balance on the Revolving Facility was zero as of June 30, 2025 and December 31, 2024, respectively. As of June 30, 2025, we were compliant with all financial covenants.

Vehicle Loans

We periodically enter into vehicle loans. Interest rates on these vehicle loans range from 4.56% to 5.68%. The outstanding balance on the vehicle loans as of June 30, 2025 was less than $0.1 million.

For additional information, see Note 6, Debt, in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations from those described in the Form 10-K.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate

Table of Contents

our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” in the Form 10-K and the notes to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. During the six months ended June 30, 2025, there were no material changes to our critical accounting policies from those discussed in the Form 10-K.

Recent Accounting Pronouncements

A description of recently adopted and issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2, Summary of Significant Accounting Policies, to our condensed consolidated financial statements, included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities.

As of June 30, 2025 and December 31, 2024, the outstanding amounts related to our 2020 Credit Facility incur interest fees at variable interest rates and are affected by changes in the general level of market interest rates. However, there was no outstanding balance on the 2020 Credit Facility as of June 30, 2025 and December 31, 2024.

Foreign Currency Exchange Risk

We transact business globally in multiple currencies and hence have foreign currency risks related to our net sales, cost of goods sold and operating expenses. We use derivative financial instruments to reduce our net exposure to foreign currency fluctuations. Our objective in managing exposure to foreign currency fluctuations is to reduce the volatility caused by foreign exchange rate changes on the earnings, cash flows and financial position of our international operations. We generally target to hedge a majority of our forecasted yearly foreign currency exchange exposure through a 24-month rolling layered approach and leave a portion of our currency forecast floating at spot rate. Our currency forecast and hedge positions are reviewed quarterly. The gains and losses on the forward contracts associated with our balance sheet positions are recorded in ‘‘Other income (expense), net” in the condensed consolidated statements of operations appearing elsewhere in this Quarterly Report on Form 10-Q.

The total notional values of our forward exchange contracts were $89.2 million and $107.4 million as of June 30, 2025 and December 31, 2024, respectively. The derivatives on the forward exchange contracts resulted in an unrealized gain of $3.9 million for the six months ended June 30, 2025, and we estimate that a 10% strengthening or weakening of the U.S. dollar would have resulted in an approximately $1.2 million gain or loss.

A portion of our cash and cash equivalents are denominated in foreign currencies. As of June 30, 2025, a 1% change in the value of the U.S. dollar compared to foreign currencies would have caused our cash and cash equivalents to decrease or increase by $0.1 million.

Tariff and Inflation Risks

Inflation generally affects us by increasing our cost of transportation, labor and manufacturing costs. In recent years, we have seen fluctuating transportation costs caused by global supply chain disruptions or geopolitical instability and general inflation effects, which may cause pressure on our costs and margins. More specifically, we source a large amount of our finished goods from international countries, which exposes us to international supply chain inflation, particularly ocean freight, and to changes in the strength of the U.S. dollar. In the six months ended June 30, 2025, general inflationary pressures continue to increase the other elements of our cost of goods and operating expenses. During the first quarter of 2025, various tariffs were announced on imports into the U.S. On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus significant additional country-specific tariffs for select trading partners, on all U.S. imports. Some of these tariff announcements have since been followed by announcements of limited exemptions and temporary pauses. The actual future tariff environment is quite uncertain.. The imposition of the baseline 10% tariff will increase our

Table of Contents

costs of goods sold. The uncertainty of future tariffs could also cause disturbances in ocean shipping capacity that could effect our ability to secure ocean freight containers for our products, and create inflationary effects on our costs, in addition to the direct impact of tariffs.

Credit Risk

We are exposed to concentration of credit risk from our major customers. In the six months ended June 30, 2025, sales to two customers represented approximately 45% of our consolidated net sales. We have not experienced credit issues with these customers. We maintain provisions for potential credit losses and evaluate the solvency of our customers on an ongoing basis to determine if additional allowances for doubtful accounts and customer credits need to be recorded. Significant economic disruptions or a slowdown in the economy could result in significant additional charges.

Item 4. Controls and Procedures.

Limitations on effectiveness of controls and procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of disclosure controls and procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of June 30, 2025, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in various claims and legal proceedings related to claims arising out of our operations. We are not currently a party to any material legal proceedings, including any such proceedings that are pending or threatened, of which we are aware.

Item 1A. Risk Factors.

Please refer to Part I, Item 1A. "Risk Factors" of our Form 10-K for the fiscal year ended December 31, 2024 for a description of certain significant risks and uncertainties to which our business, financial condition and results of operations are subject. There have been no material changes to these risk factors as of June 30, 2025.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The Company did not sell any equity securities during the three months ended June 30, 2025 that were not registered under the Securities Act.

The following table provides information regarding repurchases of our Common Stock during the three months ended June 30, 2025:


Period	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)	Approximate Dollar Value of Shares That May be Purchased Under the Plans or Programs
				(In millions)



April 1, 2025 - April 30, 2025	284,728	$30.04	867,947	$42.1
May 1, 2025 - May 31, 2025	—	$—	—	$—
June 1, 2025 - June 30, 2025	—	$—	—	$—

(1) On October 30, 2023, the Company's Board of Directors approved a share repurchase program ("Repurchase Program") authorizing the Company to repurchase up to $40.0 million of Common Stock, which was increased to a total of $65.0 million on April 28, 2025. Shares of Common Stock may be repurchased under the Repurchase Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. To the extent not retired, shares of Common Stock repurchased under the Repurchase Program will be placed in the Company's treasury shares. The extent to which the Company repurchases shares of Common Stock and the timing of such repurchases will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company. The Repurchase Program has no time limits, and may be suspended or discontinued at any time. During the three months ended June 30, 2025, the Company repurchased 284,728 shares at a cost of $8.6 million under the Repurchase Program.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

On May 8, 2025, Verlinvest Beverages SA, a significant stockholder of the Company, completed a block sale of 3,766,762 shares of the Company’s common stock at a price of $34.25 per share in a private transaction facilitated by Bank

Table of Contents

of America Securities, Inc. The transaction was executed pursuant to Rule 144 under the Securities Act of 1933, as amended.

Following the transaction, Verlinvest Beverages SA beneficially owns approximately 12.5% of the Company’s outstanding common stock, down from 19.1% prior to the transaction.

The transaction does not affect the Company’s capital structure or operations. This sale was undertaken as part of Verlinvest Beverages SA’s ongoing portfolio management strategy and does not reflect any disagreement with the Company’s management or operations.

Rule 10b5-1 Trading Plans

In accordance with the disclosure requirements set forth in Item 408(a) of Regulation S-K, the following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act), director, or entity controlled by such officer or director who adopted or terminated a contract, instruction, or written plan for the sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) during the quarterly period ended June 30, 2025:

Name

Title

Action Taken

Date of Action

Duration of Trading Arrangement

Aggregate Number of Securities to be Sold

Corey Baker

Chief Financial Officer

Adoption

May 12, 2025

August 11, 2025 to March 31, 2026

Up to 10,000 shares of Common Stock, subject to a daily maximum of 1,000 shares

The Michael Kirban 2012 Trust

A trust controlled by Michael Kirban (Co-Founder, Executive Chairman and Chairman of the Board)

Adoption

June 5, 2025

September 4, 2025 to September 30, 2026

Up to 150,000 shares of Common Stock, subject to a daily maximum of 30,000 shares

Ira Liran

Director

Adoption

May 7, 2025

August 8, 2025 to August 10, 2026

Up to 180,000 shares of Common Stock

The Ira Liran 2012 Family Trust

A trust controlled by Ira Liran

Adoption

May 7, 2025

August 8, 2025 to August 10, 2026

Up to 270,000 shares of Common Stock

Charles Van Es

Chief Sales Officer

Adoption

June 13, 2025

September 12, 2025 to March 15, 2026

Up to 60,000 shares of Common Stock

Other than as disclosed above, no other officer, director or entity controlled by such officer or director adopted, modified or terminated a contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement.

Table of Contents

Item 6. Exhibits.

Exhibit
Number

Exhibit Description

Incorporated by Reference

Filed /
Furnished
Herewith

Form

File No.

Exhibit

Filing Date

3.1

Second Amended and Restated Certificate of Incorporation.

8-K

001-40950

3.1

10/25/21

3.2

Amended and Restated Bylaws.

8-K

001-40950

3.2

10/25/21

4.1

Specimen Common Stock Certificate of The Vita Coco Company, Inc.

S-1

333-259825

4.1

9/27/21

4.2+

Registration Rights Agreement, by and among The Vita Coco Company, Inc. and certain security holders of The Vita Coco Company, Inc., dated as of October 20, 2021.

8-K

001-40950

10.1

10/25/21

4.3+

Investor Rights Agreement, among The Vita Coco Company, Inc., Verlinvest Beverages SA, Michael Kirban and Ira Liran, dated as of October 20, 2021.

8-K

001-40950

10.2

10/25/21

4.4

Form of Indenture

S-3

333-271583

4.4

5/2/23

10.1+X

Third Amendment to the Manufacturing and Purchasing Agreement, by and between Century Pacific Agricultural Ventures, Inc. and All Market Singapore Pte. Ltd, dated as of June 12, 2025.

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101.INS

Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

Table of Contents

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

_______________________

* Filed herewith.

** Furnished herewith.

+ Certain portions of this exhibit (indicated by “####”) have been redacted pursuant to Regulation S-K, Item 601(a)(6).

X Certain portions of this exhibit (indicated by "[***]") have been redacted pursuant to Regulations S-K, Item 601(b)(10)(iv).

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	THE VITA COCO COMPANY, INC.

Date: July 30, 2025	By:	/s/ Martin Roper
		Martin Roper
		Chief Executive Officer and Director
		(Principal Executive Officer)

Date: July 30, 2025	By:	/s/ Corey Baker
		Corey Baker
		Chief Financial Officer
		(Principal Financial Officer)

Source: View Original Filing on SEC EDGAR

FAQ

How much did The Vita Coco Company (COCO) earn per share in Q2 2025?

Diluted EPS was $0.38, up from $0.32 in Q2 2024.

What was Vita Coco’s revenue growth in the second quarter of 2025?

Net sales rose 17% year over year to $168.8 million.

Why did Vita Coco’s gross margin decline in Q2 2025?

Higher input, freight and logistics costs, alongside marketing spend, lowered gross margin to 36.3%, down 440 basis points YoY.

How much cash does COCO have and is it carrying debt?

As of 6/30/25, the company held $167 million in cash and had no outstanding borrowings on its $60 million revolver.

What is the status of the share repurchase program?

COCO repurchased 284,728 shares for $8.6 m in Q2; $42.1 m remains authorized.

How significant are tariffs to Vita Coco’s cost structure?

A 10% baseline U.S. import tariff is already applied; a proposed 50% tariff on Brazilian imports could materially raise COGS if enacted.

How reliant is Vita Coco on major customers?

Two customers account for 45% of year-to-date net sales, indicating high customer concentration risk.

[10-Q] The Vita Coco Company, Inc. Quarterly Earnings Report

Insights

FAQ

How much did The Vita Coco Company (COCO) earn per share in Q2 2025?

What was Vita Coco’s revenue growth in the second quarter of 2025?

Why did Vita Coco’s gross margin decline in Q2 2025?

How much cash does COCO have and is it carrying debt?

What is the status of the share repurchase program?

How significant are tariffs to Vita Coco’s cost structure?

How reliant is Vita Coco on major customers?

NASDAQ:COCO

COCO Rankings

COCO Latest News

COCO Latest SEC Filings

COCO Stock Data

Trending News

[10-Q] The Vita Coco Company, Inc. Quarterly Earnings Report

Insights

Equity Analyst neutral

Risk Analyst neutral

FAQ

How much did The Vita Coco Company (COCO) earn per share in Q2 2025?

What was Vita Coco’s revenue growth in the second quarter of 2025?

Why did Vita Coco’s gross margin decline in Q2 2025?

How much cash does COCO have and is it carrying debt?

What is the status of the share repurchase program?

How significant are tariffs to Vita Coco’s cost structure?

How reliant is Vita Coco on major customers?

NASDAQ:COCO

COCO Rankings

COCO Latest News

COCO Latest SEC Filings

COCO Stock Data